Page last updated: 2024-12-05

lomustine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Lomustine, also known as CCNU, is an alkylating antineoplastic agent used in the treatment of various cancers, including brain tumors, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. Its synthesis involves a complex multi-step process starting with a nitrosation reaction of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Lomustine exerts its antineoplastic effects by alkylating DNA, preventing its replication and ultimately leading to cell death. It is studied for its potential to treat different cancers, including glioblastoma, multiple myeloma, and pancreatic cancer. Due to its ability to cross the blood-brain barrier, lomustine is particularly effective in treating brain tumors. Its importance lies in its significant contribution to the management of various cancers, especially those affecting the central nervous system. However, its use is associated with several side effects, including bone marrow suppression, nausea, and vomiting, which necessitate careful monitoring during treatment.'

Cross-References

ID SourceID
PubMed CID3950
CHEMBL ID514
CHEBI ID6520
SCHEMBL ID3995
MeSH IDM0012676

Synonyms (134)

Synonym
AB00173884-03
AB00173884-04
AB00173884-02
NCIMECH_000220
NCI60_041743
nsc79037
belustine
1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea
urea, 1-(2-chloroethyl)-3-cyclohexyl)-1-nitroso-
cecenu
nci-c04740
1-(2-chloroethyl)-3-cyclohexylnitrosourea
ccnu
chloroethylcyclohexylnitrosourea
1-nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-
cinu
urea, 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-
nsc-79037
urea, n-(2-chloroethyl)-n'-cyclohexyl-n-nitroso-
n-(2-chloroethyl)-n'-cyclohexyl-n-nitrosourea
icig 1109
wln: l6tj amvnno&2g
nsc 79037
ceenu
sri 2200
brn 2125058
ccnu [chloroethyl nitrosoureas]
lomustinum [inn-latin]
ccris 860
rb 1509
(chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea
hsdb 6519
ai3-52779
lomustina [inn-spanish]
1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea [chloroethyl nitrosoureas]
einecs 235-859-2
(cloro-2-etil)-1-cicloesil-3-nitrosourea [italian]
1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea
13010-47-4
lomustine ,
C07079
DB01206
cyclohexyl chloroethyl nitrosourea
D00363
gleostine (tn)
lomustine (usp/inn)
NCGC00167466-01
HMS2090A17
chebi:6520 ,
ccn-u
CHEMBL514
AKOS005766022
A806019
lomustinum
7brf0z81kg ,
lomustine [usan:inn:ban]
unii-7brf0z81kg
(cloro-2-etil)-1-cicloesil-3-nitrosourea
gleostine
lomustina
tox21_112470
cas-13010-47-4
dtxcid103222
dtxsid2023222 ,
pharmakon1600-01502301
nsc-759635
nsc759635
L0251
FT-0627972
NCGC00167466-03
AM20070540
lomustine [who-dd]
1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea [iarc]
lomustine [vandf]
lomustine [ep monograph]
lomustine [hsdb]
lomustine [usan]
lomustine [mart.]
lomustine [orange book]
lomustine [inn]
lomustine [usp-rs]
lomustine [usp monograph]
lomustine [mi]
S1840
2-chloro-n-(cyclohexyl-c-hydroxycarbonimidoyl)-n-nitrosoethan-1-amine
gtpl7214
CCG-213022
CS-1461
HY-13669
SCHEMBL3995
tox21_112470_1
NCGC00167466-02
mfcd00012392
DS-1269
3-(2-chloroethyl)-1-cyclohexyl-3-nitrosourea
GQYIWUVLTXOXAJ-UHFFFAOYSA-N
1-(2-chloroethyl)-1-[(cyclohexylamino)carbonyl]-2-oxohydrazine #
W-108355
AB00173884_06
AB00173884_05
AC-8062
SR-05000001497-3
sr-05000001497
lomustine, united states pharmacopeia (usp) reference standard
lomustine, european pharmacopoeia (ep) reference standard
HMS3655I16
SR-05000001497-1
lomustine, >=98%
SW220040-1
bdbm50247919
BCP06551
1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea13010-47-4nci60_0417431-(2-chloroethyl)-3-cyclohexylnitrosourea1-nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-be
Q415378
lomustine (ceenu) ,
ccnu; nsc 79037
EN300-118685
lomustine- bio-x
BL164634
lomustine (mart.)
lucostine
lomustina (inn-spanish)
wr-139017
1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (iarc)
prava
lomustinum (inn-latin)
lomustine (ep monograph)
rb-1509
lomeblastin
lomustine (usp monograph)
l01ad02
lucostin
chloroethylcyclo-hexylnitrosourea
lomustine (usp-rs)
belustin

Research Excerpts

Overview

Lomustine is a well-accepted, first-line chemotherapy for dogs with HS, but its specific utility in dogs with HPHS has not been previously reported. Lomustin is a nitrosurea that crosses the blood brain barrier and there is evidence to suggest that temozolomide may reverse resistance to lomUSTine.

ExcerptReferenceRelevance
"Lomustine is a well-accepted, first-line chemotherapy for dogs with HS, but its specific utility in dogs with HPHS has not been previously reported."( Lomustine chemotherapy for the treatment of presumptive haemophagocytic histiocytic sarcoma in Flat-coated Retrievers.
Elliott, J, 2018
)
2.64
"Lomustine is a treatment option for patients with high-grade glioma."( Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
Gruber, HE; Huang, TT; Ibañez, CE; Jolly, DJ; Lopez Espinoza, F; Mendoza, D; Robbins, JM; Yagiz, K, 2016
)
1.41
"Lomustine is a nitrosurea that crosses the blood brain barrier and there is evidence to suggest that temozolomide may reverse resistance to lomustine."( A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
Bate, SC; Beirne, DA; Eisen, TG; Gibbens, IM; Gore, ME; Hughes, SA; Larkin, JM; Patel, PM; Thomas, K, 2007
)
1.38
"Lomustine is a commercially available chloroethyl nitrosourea compound whose antitumor activity in vitro and in animal tumor models exceeds its activity in humans. "( A phase I trial of weekly lomustine in patients with advanced cancer.
Benjamin, RS; Gorski, CC; Koller, CA; Legha, SS; Papadopoulos, NE; Plager, C, 1994
)
2.03

Effects

Lomustine has an acceptable efficacy and safety for use as a rescue agent in feline lymphoma.

ExcerptReferenceRelevance
"Lomustine has an acceptable efficacy and safety for use as a rescue agent in feline lymphoma."( Evaluation of lomustine as a rescue agent for cats with resistant lymphoma.
Bulman-Fleming, JC; Dutelle, AL; Lewis, CA; Rosenberg, MP, 2012
)
1.46
"Lomustine has become a popular single-agent option, but prolonged or cumulative myelosuppression can result in treatment delays, risking relapse."( Lomustine, methotrexate and cytarabine chemotherapy as a rescue treatment for feline lymphoma.
Blackwood, L; Harper, A; Smallwood, K, 2021
)
2.79
"Lomustine has an acceptable efficacy and safety for use as a rescue agent in feline lymphoma."( Evaluation of lomustine as a rescue agent for cats with resistant lymphoma.
Bulman-Fleming, JC; Dutelle, AL; Lewis, CA; Rosenberg, MP, 2012
)
1.46

Treatment

Lomustine or a combination of teniposide and cyclophosphamide also significantly increased the risk of leukemia. LomUSTine is a treatment option for patients with high-grade glioma.

ExcerptReferenceRelevance
"Lomustine is a treatment option for patients with high-grade glioma."( Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
Gruber, HE; Huang, TT; Ibañez, CE; Jolly, DJ; Lopez Espinoza, F; Mendoza, D; Robbins, JM; Yagiz, K, 2016
)
1.41
"Treatment with lomustine or a combination of teniposide and cyclophosphamide also significantly increased the risk of leukemia."( Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.
Chorus, AM; Hagenbeek, A; Noyon, R; Pinedo, HM; Somers, R; van den Belt-Dusebout, AW; van Kerkhoff, EH; van Leeuwen, FE, 1994
)
0.63

Toxicity

There is no increase in grade ≥3 adverse events after adjuvant lomustine treatment. The study will provide an assessment on whether combined procarbazine, lomUSTine, and vincristine provides an effective and safe form of treatment.

ExcerptReferenceRelevance
" The combination of adriamycin plus 5-FU was less toxic when the two agents were given simultaneously than when the 5-FU was given 24-96 hours after the adriamycin, while for the combination of adriamycin plus CCNU there was less toxicity if the CCNU was administered 24 hours after the adriamycin rather than simultaneously with it."( Rate of DNA synthesis as an indication of drug toxicity and as a guide for scheduling cancer therapy.
Alexander, JA; Wheeler, GP, 1978
)
0.26
" Our studies suggest that O6-benzylguanine analogues may have utility in mer+ tumors as an adjuvant to a variety of alkylating agents which produce a toxic lesion at the O6 position of guanine."( Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents.
Dolan, ME; Mitchell, RB; Moschel, RC; Mummert, C; Pegg, AE, 1991
)
0.28
" Recently it has been shown that less toxic analogues of RSU 1069 can be produced by the introduction of alkyl substituents to moderate the reactivity of the aziridine function."( The chemosensitizing and cytotoxic effects of RSU 1164 and RSU 1165 in a murine tumor model.
Siemann, DW, 1989
)
0.28
" Most of these toxic symptoms appeared 8-20 days after the first dose."( Acral erythema and systemic toxicity related to CHA induction therapy in acute myeloid leukemia.
Bagot, M; Cordonnier, C; Jais, JP; Kuentz, M; Landais, P; Oksenhendler, E; Roujeau, JC; Vernant, JP, 1989
)
0.28
" The exposure to O6-alkylguanines gave a greater enhancement of the toxic effects of ClEtSoSo than of CCNU."( Effect of O6-alkylguanine pretreatment on the sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents.
Dolan, ME; Pegg, AE; Young, GS, 1986
)
0.27
" CCNU in liposomes of different size and composition showed in lower doses a diminished therapeutic effectiveness in the P388 or L 1210 leukaemia and the B 16 melanoma, while in higher doses toxic deaths occurring with the free drug could be prevented totally by using liposomes."( Antineoplastic activity and toxicity of some alkylating cytostatics (cyclophosphamide, CCNU, cytostasan) encapsulated in liposomes in different murine tumour models.
Arndt, D; Fichtner, I; Reszka, R,
)
0.13
" Substitution of acetohydroxamic acid side chains at the N-1 position of the parent 3-nitropyrazole resulted in compounds which were preferentially toxic to cells treated under hypoxic conditions, and which were capable of enhancing the toxicity of CCNU in hypoxia."( Enhancement of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) toxicity by acetohydroxamic acid analogues of 3-nitropyrazole in vitro.
Hark, RR; Kende, AS; Mulcahy, RT; Wustrow, DJ, 1987
)
0.27
" Inhibition of this enzyme results in an alteration in sensitivity of the organism to the toxic effects of O2."( Effect of inhibition of glutathione reductase by carmustine on central nervous system oxygen toxicity.
Powell, SR; Puglia, CD, 1987
)
0.27
"45 times less toxic to normal tissue, although the dose-limiting organ may be different for the two routes."( Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.
Lee, FY; Workman, P, 1985
)
0.27
"Pre-treatment with the anabolic steroid nandrolone decanoate (ND) increases the LD50 of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 5-Fluorouracil (FU) in NMRI mice."( Effects of nandrolone decanoate on the toxicity and anti-tumour action of CCNU and FU in murine tumours.
Bibby, MC; Double, JA; Mughal, MA, 1981
)
0.26
"We have studied the toxic effect of the alkylating antitumor drug N'-cyclohexyl-N-(2-chloroethyl)-N-nitrosourea (lomustine, CCNU) on Escherichia coli (E."( Spin labeled antioxidants protect bacteria against the toxicity of alkylating antitumor drug CCNU.
Gadjeva, V; Lazarova, G; Zheleva, A, 2003
)
0.53
" Hence, inhibitors of the TGF-β signaling pathway require a careful identification of a safe therapeutic window and a comprehensive monitoring of the cardiovascular system."( Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study.
Azaro, A; Baselga, J; Carducci, M; Cleverly, AL; Corretti, M; Dolan, M; Fernández, MS; Gueorguieva, I; Kovacs, RJ; Lahn, MM; Maldonado, G; Pillay, NS; Romero, FL; Sepulveda-Sánchez, JM, 2015
)
0.42
"Evidently, the conclusion of this study will provide an assessment on whether combined procarbazine, lomustine, and vincristine provides an effective and safe form of treatment for recurrent high-grade glioma."( A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis.
Cai, Y; Jiang, YG; Jiang, ZH; Tan, ZG; Wang, M, 2020
)
1

Pharmacokinetics

ExcerptReferenceRelevance
" In order to enhance clinical effects of the nitrosoureas, further investigation of the design in therapeutic schedules on the basis of their pharmacokinetic characteristics will be needed."( [Cancer chemotherapy with special reference to pharmacokinetics of nitrosoureas].
Wakui, A, 1982
)
0.26
" It was found that the effectiveness of these compounds in producing pharmacokinetic effects correlated directly with their lipophilicity, viz."( Nitroimidazoles as modifiers of nitrosourea pharmacokinetics.
Lee, FY; Workman, P, 1984
)
0.27
" Data were analysed using noncompartmental pharmacokinetic methods."( Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients.
Blaschke, TF; Chao, NJ; Kastrissios, H, 1996
)
0.29
"004), the elimination half-life was 35% shorter (12."( Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors.
Joensuu, H; Kivistö, KT; Mäenpää, H; Neuvonen, PJ; Villikka, K, 1999
)
0.3
" Based on these differences, we investigated the relationship betweenthe structure of nitroxyl derivatives, their half-life in the circulation, and their MRI signal dynamic in the brain."( Nitroxyl radicals for labeling of conventional therapeutics and noninvasive magnetic resonance imaging of their permeability for blood-brain barrier: relationship between structure, blood clearance, and MRI signal dynamic in the brain.
Anzai, K; Aoki, I; Bakalova, R; Gadjeva, V; Kanno, I; Matsumoto, K; Zhelev, Z,
)
0.13
" The validated method has been successfully applied to a pharmacokinetic study of thermosensitive liposome-encapsulated lomustine containing iohexol and lomustine solution after intravenous administration to C6 glioma rats."( HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats.
Derendorf, H; Gao, J; Li, M; Liu, C; Yu, F; Zeng, Y; Zhang, B; Zhuang, L, 2011
)
0.83
" The selected LNL showed improved pharmacokinetic profile both in blood and brain in the experimental mice models along with negligible hemolysis in mice blood cells."( Lomustine Incorporated Lipid Nanostructures Demonstrated Preferential Anticancer Properties in C6 Glioma Cell Lines with Enhanced Pharmacokinetic Profile in Mice.
Barik, B; Kumar, LA; Pattnaik, G; Satapathy, BS, 2021
)
2.06

Compound-Compound Interactions

We investigated the effects of lomustine combined with Toca 511 + 5-FC in syngeneic orthotopic glioma models. This study did not meet its primary end point of PFS prolongation with cediranib.

ExcerptReferenceRelevance
" In the first phase, 14 patients (Group A) with progressive neurologic dysfunction following primary treatment were treated with DTIC alone (8 patients) or in combination with CCNU or methyl CCNU (6 patients) and evaluated for change in neurologic status."( Treatment of grade III and IV astrocytoma with dimethyl triazeno imidazole carboxamide (DTIC, NSC-45388) alone and in combination with CCNU (NSC-79037) or methyl CCNU (MeCCNU, NSC-95441).
Baxter, D; Cunningham, TJ; Horton, J; Nelson, L; Olson, KB; Rosenbaum, C; Sponzo, RW; Taylor, SG, 1975
)
0.25
" Data from other centers have shown that augmentation of remissions for melanoma patients occurred when BCG was combined with DTIC, vincristine, and allogeneic tumor cells."( Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Burgess, MA; Gottlieb, J; Gutterman, JU; Hersh, EM; Mavligit, GM; Reed, R, 1976
)
0.26
" From 1980 to 1982, 96 patients with SCLC were treated, 37 of whom by chemotherapy combined with surgery."( [Chemotherapy combined with selective resection in small cell lung cancer--analysis of 239 patients].
Cao, YF; Chen, YR; Fang, MS; Huang, OL; Liao, ML; Wu, SC; Wu, SF; Wu, SZ; Xu, CW; Yang, XF, 1986
)
0.27
" 1984, 35 patients with SCLC proved by pathology or cytology, were treated by cyclophosphamide + methotrexate + CCNU (CMC) regimen combined with surgery in our hospital."( [CMC chemotherapy regimen combined with surgery of small cell lung cancer (SCLC)].
Cao, YF; Chen, YR; Huang, OL; Liao, ML; Xu, CW; Zhou, YZ, 1986
)
0.27
" They were randomly assigned to receive one of the three drug combination regimens or to 5-FU alone administered by rapid injection in 5-day course."( Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group.
Cullinan, SA; Krook, JE; Mailliard, JA; Moertel, CG; O'Connell, MJ; Poon, MA; Tschetter, LK; Wieand, HS, 1994
)
0.29
"This EORTC multicentre study analysed the efficacy and tolerability in patients with metastatic uveal melanoma of BOLD chemotherapy in combination with recombinant interferon alpha-2b."( Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.
Gore, M; Hahka-Kemppinen, M; Hansson, J; Humblet, Y; Kivelä, T; Kloke, O; Kruit, WH; Kumpulainen, E; Parvinen, LM; Pyrhönen, S; Suciu, S; Vuoristo, MS, 2003
)
0.63
"This randomized phase II study was designed to compare the efficacy and tolerability of dacarbazine (DTIC) and bleomycin, vincristine, lomustine and DTIC (BOLD) combined with natural interferon-alpha (nIFN-alpha) or recombinant interferon-alpha2b (rIFN-alpha2b) in patients with advanced melanoma."( Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
Hahka-Kemppinen, M; Kellokumpu-Lehtinen, P; Korpela, M; Parvinen, LM; Pyrhönen, S; Seppä, H; Vuoristo, MS, 2005
)
0.77
" Lomustin in combination with hyperfractionated radiation therapy was found to have no effect on the survival of patients with glioblastoma and anaplastic astrocytoma."( [Results of hyperfractionated radiation therapy used in combination with lomustin in malignant gliomas of the brain].
Balkanov, AS; Kachkov, IA; Makarenko, MF; Poliakov, PIu,
)
0.13
"To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU."( High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.
Deckert, M; Feuerhake, F; Finke, J; Ihorst, G; Illerhaus, G; Marks, R; Müller, F; Ostertag, C, 2009
)
0.35
"Intrinsic subtypes are highly prognostic in EORTC 26951 and improve outcome prediction when combined with other prognostic factors."( Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu
de Rooi, J; den Dunnen, WF; Eilers, PH; Erdem-Eraslan, L; French, PJ; Gorlia, T; Gravendeel, LA; Idbaih, A; Kros, JM; Sillevis Smitt, PA; Spliet, WG; Teepen, JL; van den Bent, MJ; Wesseling, P, 2013
)
0.61
"A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recent in in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma."( Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Ashby, LS; Batchelor, TT; Campone, M; Cher, L; Degroot, J; Gattamaneni, R; Jain, RK; Jürgensmeier, JM; Liu, Q; Mason, W; Mikkelsen, T; Mulholland, P; Nabors, LB; Neyns, B; Payer, F; Phuphanich, S; Rosenthal, M; Sorensen, AG; van den Bent, M; Wick, A; Xu, J, 2013
)
0.81
"This study did not meet its primary end point of PFS prolongation with cediranib either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma, although cediranib showed evidence of clinical activity on some secondary end points including time to deterioration in neurologic status and corticosteroid-sparing effects."( Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Ashby, LS; Batchelor, TT; Campone, M; Cher, L; Degroot, J; Gattamaneni, R; Jain, RK; Jürgensmeier, JM; Liu, Q; Mason, W; Mikkelsen, T; Mulholland, P; Nabors, LB; Neyns, B; Payer, F; Phuphanich, S; Rosenthal, M; Sorensen, AG; van den Bent, M; Wick, A; Xu, J, 2013
)
0.81
" On the basis of the findings reported herein, a dose of 60 mg/m(2) of CCNU combined with 250 mg/m(2) of CTX (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs."( Tolerability of lomustine in combination with cyclophosphamide in dogs with lymphoma.
Bailey, DB; Flory, AB; Intile, JL; Kiselow, MA; Malone, EK; Rassnick, KM,
)
0.48
"Toca 511, a gamma retroviral replicating vector encoding cytosine deaminase, used in combination with 5-fluorocytosine (5-FC) kills tumor by local production of 5-fluorouracil (5-FU), inducing local and systemic immunotherapeutic response resulting in long-term survival after cessation of 5-FC."( Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
Gruber, HE; Huang, TT; Ibañez, CE; Jolly, DJ; Lopez Espinoza, F; Mendoza, D; Robbins, JM; Yagiz, K, 2016
)
0.69
"We investigated the effects of lomustine combined with Toca 511 + 5-FC in syngeneic orthotopic glioma models."( Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
Gruber, HE; Huang, TT; Ibañez, CE; Jolly, DJ; Lopez Espinoza, F; Mendoza, D; Robbins, JM; Yagiz, K, 2016
)
0.97
" Rejection of tumor rechallenge occurred after treatment with Toca 511 + 5-FC or combined with lomustine, but not with lomustine + 5-FC."( Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
Gruber, HE; Huang, TT; Ibañez, CE; Jolly, DJ; Lopez Espinoza, F; Mendoza, D; Robbins, JM; Yagiz, K, 2016
)
0.9
"To compare the efficacy and safety of BD regimen combined with cyclophosphamide(CTX) and pirarubicin chemotherapy(P-CAD) for patients with relapse/refractory multiple myeloma(MM)."( [Effect of BD Regimen Combined with Cyclophosphamide and Pirarubicin in Treatment of Relapse/Refractory Multiple Myeloma].
Chen, YL; Ma, XH; Qiu, ZY; Ren, CA; Wang, YF; Xu, WJ, 2016
)
0.43
"BD regimen combined with cyclophosphamide and pirarubicin chemotherapy can improve the response rate of patients with relapse/refractory multiple myeloma, and shows the trend of prolonging PFS and survival times."( [Effect of BD Regimen Combined with Cyclophosphamide and Pirarubicin in Treatment of Relapse/Refractory Multiple Myeloma].
Chen, YL; Ma, XH; Qiu, ZY; Ren, CA; Wang, YF; Xu, WJ, 2016
)
0.43
" Using immunocompetent orthotopic glioma mouse models, we identified strong anti-glioma activity of L19TNF in combination with the alkylating agent CCNU, which cured the majority of tumor-bearing mice, whereas monotherapies only had limited efficacy."( Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell-dependent regression of glioblastoma.
Amit, I; Becher, B; Bühler, M; De Luca, R; Di Nitto, C; Hemmerle, T; Katzenelenbogen, Y; Kirschenbaum, D; Look, T; Neri, D; Puca, E; Ravazza, D; Rindlisbacher, L; Roth, P; Stucchi, R; Weiner, A; Weiss, T; Weller, M, 2023
)
0.91

Bioavailability

Lomustine bioavailability was obviously increased in C6 glioma rat plasma. The first-in-human dose study had three parts (Part A, dose escalation, Part B, safety combination with lmustine, Part C, relative bioavailability study)

ExcerptReferenceRelevance
"Differential pulse polarographic assay of intact nitrosoureas revealed the lower bioavailability of CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea) in stomach and liver after oral administration to rats in comparison to BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea); blood levels of CCNU were below the detection limit of the method (20 ng)."( Pharmacokinetics of nitrosoureas: comparison of 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) after oral and intravenous administration to rats.
Bartosek, I; Cattaneo, MT; Russo, RG, 1984
)
0.27
" Compared with non-heated group, the bioavailability of lomustine was obviously increased in C6 glioma rat plasma."( HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats.
Derendorf, H; Gao, J; Li, M; Liu, C; Yu, F; Zeng, Y; Zhang, B; Zhuang, L, 2011
)
0.87
" Design The first-in-human dose study had three parts (Part A, dose escalation, n = 39; Part B, safety combination with lomustine, n = 26; Part C, relative bioavailability study, n = 14)."( Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
Azaro, A; Baselga, J; Blakeley, J; Braña, I; Calvo, E; Carducci, M; Cleverly, A; Desaiah, D; Estrem, ST; Gueorguieva, I; Holdhoff, M; Lahn, MM; Paz-Ares, L; Pillay, NS; Rodón, J; Seoane, J; Sepulveda-Sánchez, JM; Sicart, E, 2015
)
0.63
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Lomustine was administered at a median starting dosage of 67 mg/m(2), PO, every 21 days until 5 doses were given or disease progression was observed. 38 cats with measurable, histologically or cytologically confirmed MCTs treated with lomustin at a dosage > or = 50 mg/ m(2)

ExcerptRelevanceReference
"Experiments are described in which dose-response data have been obtained for EMT6 mouse tumour cells growing in vivo and exposed to various cytotoxic agents."( The sensitivity to cytotoxic agents of the EMT6 tumor in vivo. Comparative response of lung nodules in rapid expotential growth and of the solid flank tumour.
Bleehen, NM; Twentyman, PR, 1976
)
0.26
" Piperidino-CNU and Ethylmethanesulfonato-CNU also effected cures; however, only Piperidino-CNU in one dosage effected a median survival time of greater than 90 days."( Examination of four newly synthesized 2-chloroethylnitrosoureas in comparison with BCNU, CCNU, MeCCNU, chlorozotocin and hydroxyethyl-CNU in preterminal rat leukemia L 5222.
Eisenbrand, G; Fiebig, HH; Zeller, WJ, 1979
)
0.26
" On the other side, dosage and the interval between cycles of chemotherapy appear to be a determining factor in the activity, but the limits are very narrow."( [A study of the use of sequential chemotherapy in 176 cases of glioblastoma (author's transl)].
Buge, A; Poisson, M; Pouillart, P, 1978
)
0.26
" The depression of platelets and white blood cells was mild after a single dosage of 40 mg/kg CCNU which recovered on about the 6th day."( Brain tumor chemotherapy using a rat glioma model.
Mennel, HD; Tamura, M; Zülch, KJ, 1979
)
0.26
"34 patients operated on for malignant gliomas were successively treated by combination chemotherapy with VM26 and CCNU and conventional radiation therapy with an average dosage of 5,800 Rads, six months after surgery."( Malignant gliomas treated after surgery by combination chemotherapy and delayed radiation therapy. Part II. Tolerance to irradiation after chemotherapy.
Bataini, JP; Hauw, JJ; Mashaly, R; Metzger, J; Pertuiset, BF; Poisson, M; Pouillart, P, 1979
)
0.26
" The treatment dosage was 130 mg/m2 for patients with adequate bone marrow reserve and 100 mg/m2 for those with compromised bone marrow."( Treatment of advanced malignancy with CCNU (NSC 79037): a phase II cooperative study with long-term follow up.
Armstrong, DM; Aust, JB; Cruz, AB; Fletcher, WS; Metter, G; Richardson, JD; Wilson, WL, 1976
)
0.26
" Wehn 1-(-chloroethyl)-3-cyclohexyl-1-nitrosourea was given in divided dosage at an interval of 8 days, marked and persistent tumor regression was observed."( Chemotherapy of a human malignant melanoma transplanted in the nude mouse.
Jacobsen, GK; Povlsen, CO, 1975
)
0.25
" The three drugs show similar threshold-type dose-response survival curves on asynchronous cells treated for 1 hr."( A comparison of the lethal effects of three nitrosourea derivatives on cultured human lymphoma cells.
Drewinko, B; Gottlieb, JA; Loo, TL, 1976
)
0.26
" An important cause of reduced benefit from chemotherapy among elderly patients may be the reduced dosage of cisplatin."( Cisplatin combination chemotherapy for elderly patients with urothelial tumours.
Amato, R; Dexeus, FH; Finn, L; Fitz, K; Logothetis, CJ; Sella, A, 1991
)
0.28
" All patients required dosage modification for toxicity."( Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine.
Evans, AE; Lefkowitz, IB; Packer, RJ; Schut, L; Siegel, KR; Sutton, LN, 1990
)
0.49
" In a panel of 12 human cancer cell lines [melanoma (4), ovary (2), head and neck (3), lung (1), bladder (1), breast (1)], the dose-response curves of S 10036 (0-100 microM) were similar to those obtained with equimolar concentrations of BCNU and CCNU; they indicated a moderately more marked effect for two and an equal effect for six melanoma cell lines with S 10036 as compared with BCNU."( In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea.
Bizzari, JP; Deloffre, P; Etienne, MC; Fischel, JL; Formento, P; Frenay, M; Gioanni, J; Milano, G, 1990
)
0.28
" Nor did the analysis of life quality and of changes in clinical performance show any benefit in supplementing surgery and radiation therapy with CCNU chemotherapy at the dosage used."( Quality of survival of patients with brain gliomas treated with postoperative CCNU and radiation therapy.
Bendarzewska, B; Bielawski, A; Dabrowska, A; Gościński, I; Lopatkiewicz, J; Markiewicz, P; Peszyński, J; Szymona, J; Trojanowski, T; Turowski, K, 1989
)
0.28
" The CVPP schedule gave: (1) a constant drug dosage for each patient independent of body surface or weight; and (2) a total drug dosage dependent on haematological tolerance, since the treatment was given for 21 days or until the leukocyte count dropped to 2 x 10(9) l-1."( Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease.
Bonichon, F; Chauvergne, J; de Mascarel, I; Eghbali, H; Hoerni, B; Lagarde, P, 1989
)
0.28
" Another dosage and timing of misonidazole administration in relation to the irradiation schedule, and a consideration of effects of concomitant drugs like dexamethasone and phenytoin are discussed."( Combined modality treatment of operated astrocytomas grade 3 and 4. A prospective and randomized study of misonidazole and radiotherapy with two different radiation schedules and subsequent CCNU chemotherapy. Stage II of a prospective multicenter trial of
Ganz, JC; Hagen, S; Hatlevoll, R; Kristiansen, K; Lindegaard, KF; Mella, O; Nesbakken, R; Ringkjöb, R; Rosengren, B; Torvik, A, 1985
)
0.27
" The radiation dose ranged from 3000 to 4650 rad and the oral CCNU dosage from 300 mg to 1050 mg."( Sudden onset of blindness in patients treated with oral CCNU and low-dose cranial irradiation.
Kleinschmidt-Demasters, BK; Perez, GM; Wilson, WB, 1987
)
0.27
"5 g/M2 every six weeks, with dosage adjustments for myelotoxicity."( Misonidazole and CCNU chemotherapy for recurrent primary brain tumor.
Fulton, DS; McKinnon, S; Tanasichuk, H; Urtasun, RC, 1987
)
0.27
" A preliminary SCE dose-response curve was determined with a broad range of doses of CCNU using a single donor."( Sister chromatid exchange induction near the baseline with low doses of the alkylating agent CCNU.
Best, RG; McKenzie, WH, 1988
)
0.27
" These data are of importance for the optimal sequencing and dosing of these drugs for future clinical trials."( Schedule-dependent potentiation of lomustine cytotoxicity by amphotericin B in mice.
Chabot, G; Dieckman, J; Valeriote, F, 1986
)
0.55
" Attenuation schedules and data relating to the total administered dosage should be provided."( Chemotherapy for soft tissue sarcoma.
Brennan, MF; DeCosse, JJ; Greenall, MJ; Magill, GB, 1986
)
0.27
" The chemotherapeutic agent was administered simultaneously with the single sensitizer dose or 3 h into the chronic sensitizer dosing schedule."( Increased therapeutic benefit through the addition of misonidazole to a nitrosourea-radiation combination.
Hill, SA; Siemann, DW, 1986
)
0.27
" The therapy is to be used effectfully only then, when indication, dosage and control of the patients are performed critically and exactly."( [Chemotherapy of malignant solid tumors].
Knöll, P; Siering, H, 1980
)
0.26
" Dose-response relationships of 3 triple-drug combinations and their component agents were explored, allowing the relative contributions of single agents in each combination to be assessed."( Experimental combination and single-agent chemotherapy in human lung-tumour xenografts.
Jones, JM; Peckham, MJ; Shorthouse, AJ; Steel, GG, 1982
)
0.26
" Since no epidemiological data in man are available, extrapolation of animal data to man are important as well as dose-response studies in risk evaluations."( Carcinogenic N-nitroso compounds and their environmental significance.
Preussmann, R, 1984
)
0.27
" A steep dose-response relationship for the polyenes was also noted."( Potentiation of cytotoxicity of anticancer agents by several different polyene antibiotics.
Dieckman, J; Medoff, G; Valeriote, F, 1984
)
0.27
" Combination data were evaluated either by applying the simple concept that an additive combination response is equal to the sum of the single agent responses or by constructing additivity envelopes as described recently by Steel & Peckham (1979), in order to take account of non-linear dose-response curves."( Comparison of growth delay and cell survival as end-points of tumour response following treatment with combinations of cytotoxic agents.
Peacock, JH; Stephens, TC, 1980
)
0.26
" To obtain dose-response curves and quantitative comparisons of different treatments, an agar-colony assay was used to measure survival of cells from excised tumours."( Response of two mouse tumours to hyperthermia with CCNU or melphalan.
Joiner, MC; Steel, GG; Stephens, TC, 1982
)
0.26
"A dose-response relation for the cytotoxic activity of chloroethylnitrosourea cancer chemotherapeutic agents in cell culture has been developed."( Quantitative dose-response relations for the cytotoxic activity of chloroethylnitrosoureas in cell culture.
Deen, DF; Weinkam, RJ, 1982
)
0.26
" Sensitizer dose-response curves were obtained for MISO, METRO and two of the most effective agents, benznidazole (Ro 07-1051) and Ro 07-1902."( Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU.
Twentyman, PR; Workman, P, 1982
)
0.26
" We conclude that, in multidrug therapies, the continuation of corticosteroid at conventional dosage beyond the first course does not improve response rate or survival time in multiple myeloma."( Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma. Finnish Leukaemia Group.
Ala-Harja, K; Almqvist, A; Elonen, E; Hallman, H; Hänninen, A; Ilvonen, M; Isomaa, B; Järvenpää, E; Jouppila, J; Palva, IP, 1993
)
0.29
"To complete research in this type of coagulation and cancer, a multicentric randomized clinical trial was performed, including 303 patients with small cell lung cancer (SCLC), treated by the addition of aspirin at 1 g/day (a dosage at which aspirin is considered to be a platelet aggregation inhibitor) to combined chemotherapy."( No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The "Petites Cellules" Group.
Chastang, C; Fabre, C; Lebeau, B; Massin, F; Muir, JF; Vincent, J, 1993
)
0.29
" Dogs were treated with CCNU at a dosage of 90 mg/m2 body surface area every 3 weeks."( Treatment of canine mast cell tumors with CCNU (lomustine).
Cotter, SM; Engler, SJ; Kintzer, PP; London, CA; Moore, AS; Rassnick, KM; Williams, LE,
)
0.39
" A prospective evaluation of CCNU was done to determine the maximally tolerated dosage of CCNU in tumor-bearing cats."( Phase I evaluation of CCNU (lomustine) in tumor-bearing cats.
Gieger, TL; Kristal, O; Moore, AS; Myers, NC; Northrup, NC; Rassnick, KM; Ruslander, DM; Williams, LE,
)
0.43
" Parameters were evaluated by age at diagnosis, gender, ethnic origin, pre- and postsurgery Karnofsky Performance Status (KPS) score, limit and amount of surgical resection, histopathologic type, number of chemotherapy courses, time between surgery and radiotherapy, response to combined therapy, and dosage and type of radiotherapy."( Long-term follow-up in managing anaplastic astrocytoma by multimodality approach with surgery followed by postoperative radiotherapy and PCV-chemotherapy: phase II trial.
Gal, O; Kovner, F; Ron, IG; Vishne, TH, 2002
)
0.31
" Due to biohazard concerns associated with lomustine capsule reformulation, a standardized 10-mg capsule dosage was used for all cats regardless of body weight."( Hematological toxicity and therapeutic efficacy of lomustine in 20 tumor-bearing cats: critical assessment of a practical dosing regimen.
Dhaliwal, RS; Fan, TM; Hintermeister, JG; Jones, PD; Kitchell, BE; Paria, BC,
)
0.65
" For each tumor-derived cell culture, a complete dose-response curve was established for each chemotherapeutic agent tested."( Metastatic lung disease to the central nervous system: in vitro response to chemotherapeutic agents.
Burholt, DR; Donovan, M; George, LD; Kornblith, PL; Marsh, JW, 2004
)
0.32
" To improve treatment, voriconazole dosage was adapted to reach drug concentrations in cerebrospinal fluid (CSF) above the minimal fungicidal concentration and plasma specimens."( Successful treatment with voriconazole of Aspergillus brain abscess in a boy with medulloblastoma.
Burhenne, J; Foell, JL; Reiss, T; Rengelshausen, J; Staege, MS; Stiefel, M; Wawer, A, 2007
)
0.34
" Dogs received a median starting CCNU dosage of 70 mg/m2 (range, 50-100 mg/m2)."( CCNU in the treatment of canine epitheliotropic lymphoma.
Hansen, K; Johnson, JL; Lana, SE; Morrison-Collister, KE; Power, HT; Rassnick, KM; Williams, LE,
)
0.13
" Complete remission was obtained after the third dosing regimen."( Diagnosis and treatment of a feline oral mast cell tumor.
Chretin, JD; Wright, ZM, 2006
)
0.33
" Chemotherapy consisted of: (1) up to six cycles of the standard CHOP based regimen, or (2) up to six cycles of the standard CHOP based regimen with oral Semustine dosed at 120 mg (or Lomustine dosed at 100mg) on day 1 of each chemotherapy cycle."( Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo, Y; Hong, X; Li, J; Li, X; Lu, JJ; Ma, X; Wang, B, 2008
)
0.54
"Lomustine was administered at a median starting dosage of 67 mg/m(2), PO, every 21 days until 5 doses were given or disease progression was observed."( Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005).
Bannink, EO; Kaneene, JB; Mullins, MN; Obradovich, JE; Sauerbrey, ML; Van Dorp, TE, 2007
)
3.23
" The patients were divided into two groups according to the chemotherapy (3-7 treatment cycles): with DTIC-given orally daily for 5 days, every 3 weeks as a single 2200 mg/kg dose and with the combination-DTIC (the same dose) + CCNU-administered orally at a dosage of 120 mg/m(2) once every 40 days in accordance with protocols, approved by the Bulgarian Ministry of Health."( Influence of therapy on the antioxidant status in patients with melanoma.
Dimov, A; Gadjeva, V; Georgieva, N, 2008
)
0.35
"38 cats with measurable, histologically or cytologically confirmed MCTs treated with lomustine at a dosage > or = 50 mg/m(2)."( Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005).
Al-Sarraf, R; Baez, JL; Dank, G; Kristal, O; Rassnick, KM; Williams, LE; Zwahlen, CH, 2008
)
2.01
" Targeted lomustine dosage was 50 mg/m(2) in 22 cats and 60 mg/m(2) in 16 cats."( Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005).
Al-Sarraf, R; Baez, JL; Dank, G; Kristal, O; Rassnick, KM; Williams, LE; Zwahlen, CH, 2008
)
2.19
" In patients with abnormal renal function, dosage adjustment is often required to improve the renal tolerance, and also to limit the risk of extra-renal toxicities (such as haematological toxicities) induced by a drug overdosage, in those patients with reduced drug-elimination."( [Chemotherapy and renal toxicity].
Deray, G; Isnard-Bagnis, C; Janus, N; Karie, S; Launay-Vacher, V, 2008
)
0.35
" Alternative dosing regimens, such as 1-week on/1-week off, or 3-week on/1-week off, that deliver more prolonged exposure have been observed to result in higher cumulative doses than the standard 5-day regimen and may deplete tumor-derived O6-methylguanine-DNA methyltransferase (MGMT) in tumor cells, thus sensitizing tumor cells to the effects of TMZ."( [Treatment of glioma with temozolomide].
Nishikawa, R, 2009
)
0.35
" The actual CCNU dosage administered did not affect response rate or remission duration."( Combination chemotherapy with continuous L-asparaginase, lomustine, and prednisone for relapsed canine lymphoma.
Hafeman, SD; Saba, CF; Thamm, DH; Vail, DM,
)
0.38
"Prospective, open-label phase II clinical trial in which dogs with previously untreated HS were uniformly treated with CCNU as a single oral dosage of 90 mg/m2 every 4 weeks."( Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma.
Bailey, DB; Flory, AB; Intile, JL; Kiselow, MA; Kristal, O; Moore, AS; Northrup, NC; Rassnick, KM; Russell, DS,
)
0.13
" In groups 1 and 3, mean lomustine dosage was 60."( Comparison of oral administration of lomustine and prednisolone or prednisolone alone as treatment for granulomatous meningoencephalomyelitis or necrotizing encephalitis in dogs.
Boettcher, IC; Doherr, MG; Flegel, T; Henke, D; Matiasek, K; Oechtering, G; Oevermann, A, 2011
)
0.95
" No association between dosing frequency, cumulative dose, initial starting dose or concurrent medications, and increases in ALT were found."( Low apparent risk of CCNU (lomustine)-associated clinical hepatotoxicity in cats.
Chretin, JD; Musser, ML; Quinn, HT, 2012
)
0.68
" The safety component reported here, which also investigated pharmacokinetics and preliminary clinical activity, required expansion and is therefore considered a phase I part to establish a recommended dosing regimen of the combination of CCNU (90-110 mg/m(2)) and dasatinib (100-200 mg daily)."( EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.
Allgeier, A; Brandes, AA; Franceschi, E; Gorlia, T; Hegi, M; Lacombe, D; Laigle Donadey, F; Lhermitte, B; Strauss, LC; Stupp, R; van den Bent, MJ; van Herpen, C, 2012
)
0.38
" CCNU was administered per os (PO) at a targeted dosage of 60 mg/m(2) body surface area on day 0, CTX was administered PO at a targeted dosage of 250 mg/m(2) divided over days 0 through 4, and all dogs received prophylactic antibiotics."( Tolerability of lomustine in combination with cyclophosphamide in dogs with lymphoma.
Bailey, DB; Flory, AB; Intile, JL; Kiselow, MA; Malone, EK; Rassnick, KM,
)
0.48
"While maintaining a standard toceranib dosage [2."( Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.
Kurzman, ID; Pan, X; Tsimbas, K; Vail, DM, 2016
)
0.43
"Mice were dosed with either intravenous lomustine Molecular Envelope Technology (MET) nanoparticles (13 mg kg(-1)) or ethanolic lomustine (6."( Lomustine Nanoparticles Enable Both Bone Marrow Sparing and High Brain Drug Levels - A Strategy for Brain Cancer Treatments.
Chooi, KW; Fisusi, FA; Garrett, N; Lalatsa, K; Moger, J; Okubanjo, O; Satchi-Fainaro, R; Schätzlein, AG; Serrano, D; Siew, A; Stapleton, P; Summers, I; Uchegbu, IF, 2016
)
2.14
" Accomplishing this integration would enable harnessing the benefits of each method- personalized dosing of 3D printing and flexibility and speed of continuous manufacturing."( Small-Scale Continuous Drug Product Manufacturing using Dropwise Additive Manufacturing and Three Phase Settling for Integration with Upstream Drug Substance Production.
Nagy, ZK; Reklaitis, GV; Sundarkumar, V, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
alkylating agentHighly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
N-nitrosoureasA nitroso compound that is any urea in which one of the nitrogens is substituted by a nitroso group
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency33.49150.006038.004119,952.5996AID1159521
TDP1 proteinHomo sapiens (human)Potency0.01680.000811.382244.6684AID686978; AID686979
EWS/FLI fusion proteinHomo sapiens (human)Potency0.01660.001310.157742.8575AID1259256
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency63.09570.016525.307841.3999AID602332
thyroid stimulating hormone receptorHomo sapiens (human)Potency14.96010.001628.015177.1139AID1259385
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (41)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (222)

Assay IDTitleYearJournalArticle
AID97044Number of cells present measured with the Coulter counter at 25 uM conc.1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis.
AID97674percent synthesis of DNA in L1210 cells when incubated with the compound for 30 min using [3H]dUrd as radioligand at 100 uM conc.1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis.
AID119140survivors / total number of mice intracerebrally implanted leukemia L1210 at 60 mg/kg administered intraperitoneally on day 1 only. 4-5 day; 9/101980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID116972Percent increase in life span was measured in mice intracerebrally implanted leukemia L1210 at 60 mg/kg administered intraperitoneally on day 1 only.1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID118829Median day of death was measured in mice intracerebrally implanted leukemia L1210 at 80 mg/kg administered intraperitoneally on day 1.1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID130098Dose range for antitumor activity against leukemia L1210 in mice.1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antitumor evaluation of some nitrosourea and nitrogen mustard amino acid derivatives.
AID115852Activity against TLX-5 lymphoma in mice Percent increase in survival time at 80 mg/kg, 1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID119138survivors / total number of mice intracerebrally implanted leukemia L1210 at 50 mg/kg administered intraperitoneally on day 1 only. 4-5 day; 8/91980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID1149433Antitumor activity against mouse advanced Lewis lung carcinoma allografted in BDF1 mouse assessed as disease cure at 40 mg/kg, ip administered as single dose on 7th day post-tumor implantation measured for 80 days post-drug treatment1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID119139survivors / total number of mice intracerebrally implanted leukemia L1210 at 50 mg/kg administered intraperitoneally on day 1 only. 4-5 day; 8/101980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID1132739Antitumor activity against 1 ug/ml compound treated rat Walker 256 cells allografted in rat assessed as increase of host survival time cells incubated for 2 hrs with rat liver microsomes and NADPH prior to animal injection1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID66146Maximum tolerated dose required antitumor activity against Ehrlich ascites carcinoma cells in male ICR mice.1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
A new class of nitrosoureas. 4. Synthesis and antitumor activity of disaccharide derivatives of 3,3-disubstituted 1-(2-chloroethyl)-1-nitrosoureas.
AID409946Inhibition of human recombinant MAOB at 100 uM by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID152565Mean value for the exposure for P388 to the drug for a period of 40 min at pH 7.4 and 37 degree1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
An analysis of 1-(2-chloroethyl)-1-nitrosourea activity at the cellular level.
AID118827Median day of death was measured in mice intracerebrally implanted leukemia L1210 at 50 mg/kg administered intraperitoneally on day 1.1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID116971Percent increase in life span was measured in mice intracerebrally implanted leukemia L1210 at 50 mg/kg administered intraperitoneally on day 1 only.1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID1132741Antitumor activity against 0.25 ug/ml compound treated rat Walker 256 cells allografted in rat assessed as increase of host survival time cells incubated for 2 hrs with rat liver microsomes and NADPH prior to animal injection1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID97669percent synthesis of DNA in L1210 cells when incubated with the compound for 18 h using [3H]-dUrd as radioligand at 25 uM conc.1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis.
AID97584Antitumor activity against Leukemia L1210 cells in BDF1 mice at the dose of 25 mg/kg/day x 5 (ip), maximum increase in life-span1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
A new class of nitrosoureas. 4. Synthesis and antitumor activity of disaccharide derivatives of 3,3-disubstituted 1-(2-chloroethyl)-1-nitrosoureas.
AID1132759Antitumor activity against mouse TLX5 cells allografted in mouse assessed as increase in host survival time at 20 mg/kg relative to control1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID97800percent synthesis of RNA in L1210 cells when incubated with compound for 18 hr using [3H]-dThd as radioligand at 25 uM conc.1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis.
AID97801percent synthesis of RNA in L1210 cells when incubated with compound for 18 hr using [3H]-dThd as radioligand at 50 uM conc.1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID25750Pharmacokinetic parameter k2 was determined1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
An analysis of 1-(2-chloroethyl)-1-nitrosourea activity at the cellular level.
AID118826Median day of death was measured in mice intracerebrally implanted leukemia L1210 at 40 mg/kg administered intraperitoneally on day 1.1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID26811Partition coefficient (logP)1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability.
AID116973Percent increase in life span was measured in mice intracerebrally implanted leukemia L1210 at 80 mg/kg administered intraperitoneally on day 1 only.1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1133740Octanol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis of analogues of N-(2-chloroethyl)-N'-(trans-4-methylcyclohexyl)-N-nitrosourea for evaluation as anticancer agents.
AID97810percent synthesis of protein in L1210 cells when incubated with the compound for 18 hr using [3H]-L-Leu as radioligand at 25 uM conc.1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis.
AID97050Size distribution of cells at 100 uM conc.1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis.
AID97807percent synthesis of RNA in L1210 cells when incubated with compound for 30 min using [3H]dThd as radioligand at 50 uM conc.1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID477295Octanol-water partition coefficient, log P of the compound2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
AID97670percent synthesis of DNA in L1210 cells when incubated with the compound for 18 h using [3H]dUrd as radioligand at 50 uM conc.1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis.
AID97052Size distribution of cells at 50 uM conc.1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1132760Antitumor activity against mouse TLX5 cells allografted in mouse assessed as increase in host survival time at 40 mg/kg relative to control1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID118824Median day of death was measured in mice intracerebrally implanted leukemia L1210 at 30 mg/kg administered intraperitoneally on day 1.1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID114964median survival time including day-60 survivors (MST), after post implantation at the optimal dose of 32 mg/kg1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Studies on synthesis and anticancer activity of selected N-(2-fluoroethyl)-N-nitrosoureas.
AID1132737Antitumor activity against mouse TLX5 cells allografted in mouse assessed as increase in host survival time at 5 mg/kg relative to control1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID97813percent synthesis of protein in L1210 cells when incubated with the compound for 18 h uusing [3H]L-Leu as radioligand at 50 uM conc.1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis.
AID119142survivors / total number of mice intracerebrally implanted leukemia L1210 at 80 mg/kg administered intraperitoneally on day 1 only. 4-5 day; 3/81980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID23276Partition coefficient (logP)1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Antitumor structure-activity relations. Nitrosoureas vs. L-1210 leukemia.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1132752Drug metabolism in Wistar rat liver microsomes assessed as total trans-2-OH CCNU level at 50 ug/ml after 10 mins by HPLC analysis1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID119025survivors / total number of mice intracerebrally implanted leukemia L1210 at 30 mg/kg administered intraperitoneally on day 1 only. 4-5 day; 8/101980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID97805percent synthesis of RNA in L1210 cells when incubated with compound for 30 min using [3H]dThd as radioligand at 100 uM conc.1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1149525Antitumor activity against mouse advanced Lewis lung carcinoma allografted in ip dosed BDF1 mouse assessed as complete regression of established tumor administered as single dose on day 6 or 7 post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID134731Median lethal dose in L1210 (murine luekemia) inoculated mice.1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antitumor evaluation of some nitrosourea and nitrogen mustard amino acid derivatives.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1132762Antitumor activity against mouse TLX5 cells allografted in mouse assessed as increase in host survival time at 160 mg/kg relative to control1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1132744Antitumor activity against 0.5 ug/ml compound treated rat Walker 256 cells allografted in rat assessed as increase of host survival time cells incubated for 2 hrs with NADPH prior to animal injection1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID1133739Therapeutic index, ratio of LD10 for BDF1 mouse to ED50 for mouse L1210 cells allografted in ip dosed BDF1 mouse1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis of analogues of N-(2-chloroethyl)-N'-(trans-4-methylcyclohexyl)-N-nitrosourea for evaluation as anticancer agents.
AID189629The capillary permeability of radioligand was measured in Rat brain1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability.
AID119026survivors / total number of mice intracerebrally implanted leukemia L1210 at 40 mg/kg administered intraperitoneally on day 1 only. 4-5 day; 8/91980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID152566Mean value for the exposure for P388 to the drug for a period of 60 min1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
An analysis of 1-(2-chloroethyl)-1-nitrosourea activity at the cellular level.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID235241Therapeutic index value for anti-L1210 activity.1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
A new class of nitrosoureas. 4. Synthesis and antitumor activity of disaccharide derivatives of 3,3-disubstituted 1-(2-chloroethyl)-1-nitrosoureas.
AID97045Number of cells present measured with the Coulter counter at 50 uM conc.1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID97816percent synthesis of protein in L1210 cells when incubated with the compound for 30 min using [3H]L-Leu as radioligand at 100 uM conc.1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis.
AID97599Antitumor activity against Leukemia L1210 cells in male BDF1 mice at the dose of 25 mg/kg/day x5 (i.p.) expressed as maximal increase in life-span1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
A new class of nitrosoureas. 4. Synthesis and antitumor activity of disaccharide derivatives of 3,3-disubstituted 1-(2-chloroethyl)-1-nitrosoureas.
AID116427Optimal percentage of increased life span [(100 x MST treated mice / MST control mice) -100] at the optimal dose of 32 mg/kg1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Studies on synthesis and anticancer activity of selected N-(2-fluoroethyl)-N-nitrosoureas.
AID1149377Antitumor activity against mouse advanced Lewis lung carcinoma allografted in BDF1 mouse assessed as increase in host life span at 50 mg/kg, ip administered as single dose on 7th day post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID134226Toxicity against L-1210 leukemia cells in mice after intraperitoneal administration, activity is expressed as LD101980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Antitumor structure-activity relations. Nitrosoureas vs. L-1210 leukemia.
AID125581Tested for 3 log kill of leukemia cells1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Antitumor structure-activity relations. Nitrosoureas vs. L-1210 leukemia.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1132742Antitumor activity against 4 ug/ml compound treated rat Walker 256 cells allografted in rat assessed as increase of host survival time cells incubated for 2 hrs with NADPH prior to animal injection1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID23481Partition coefficient (logP)1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
An analysis of 1-(2-chloroethyl)-1-nitrosourea activity at the cellular level.
AID26180Half-life in plasma by using UV method1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Potential inhibitors of nucleotide biosynthesis. 1. Nitrosoureidonucleosides. 2.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID118828Median day of death was measured in mice intracerebrally implanted leukemia L1210 at 60 mg/kg administered intraperitoneally on day 1.1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID135724Oncostatic index (median survival time (treated)/median survival time (control) x 100); Over 50% cured.1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antitumor evaluation of some nitrosourea and nitrogen mustard amino acid derivatives.
AID116969Percent increase in life span was measured in mice intracerebrally implanted leukemia L1210 at 30 mg/kg administered intraperitoneally on day 1 only.1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1132753Drug metabolism in Wistar rat liver microsomes assessed as total cis-3-OH CCNU level at 50 ug/ml after 10 mins by HPLC analysis1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID116974Percent increase in life span was measured in mice intracerebrally implanted leukemia L1210 at 80 mg/kg administered intraperitoneally on day 1 only.1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID1132748Drug metabolism in Wistar rat liver microsomes at 50 ug/ml after 10 mins1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID119141survivors / total number of mice intracerebrally implanted leukemia L1210 at 60 mg/kg administered intraperitoneally on day 1 only. 4-5 day; 8/101980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID1149526Antitumor activity against mouse advanced Lewis lung carcinoma allografted in ip dosed BDF1 mouse assessed as disease cure administered as single dose on day 6 or 7 post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1132738Antitumor activity against 4 ug/ml compound treated rat Walker 256 cells allografted in rat assessed as increase of host survival time cells incubated for 2 hrs with rat liver microsomes and NADPH prior to animal injection1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID97051Size distribution of cells at 25 uM conc.1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID115848Activity against TLX-5 lymphoma in mice Percent increase in survival time at 100 mg/kg, 1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID1132740Antitumor activity against 0.5 ug/ml compound treated rat Walker 256 cells allografted in rat assessed as increase of host survival time cells incubated for 2 hrs with rat liver microsomes and NADPH prior to animal injection1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID235240Therapeutic index value for anti-Ehrlich activity.1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
A new class of nitrosoureas. 4. Synthesis and antitumor activity of disaccharide derivatives of 3,3-disubstituted 1-(2-chloroethyl)-1-nitrosoureas.
AID1132749Drug metabolism in Wistar rat liver microsomes at 50 ug/ml after 20 mins1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID97797percent synthesis of DNA in L1210 cells when incubated with the compound for 30 min using [3H]dUrd as radioligand at 50 uM conc.1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis.
AID97043Number of cells present measured with the Coulter counter at 100 uM conc.1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis.
AID1132751Drug metabolism in Wistar rat liver microsomes assessed as recovered total OH-CCNU derivatives level at 2.8 mg after 10 mins by HPLC analysis1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID97818percent synthesis of protein in L1210 cells when incubated with the compound for 30 min using [3H]L-Leu as radioligand at 50 uM conc.1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1895190Inhibition of sulfatase in human T98G cells assessed as reduction in fluorescence intensity at 25 uM using 2-(2-Morpholinoethyl)-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1H-benzo[de]-isoquinoline-1,3(2H)-dione a2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
New Protocol-Guided Exploitation of a Lysosomal Sulfatase Inhibitor to Suppress Cell Growth in Glioblastoma Multiforme.
AID1132761Antitumor activity against mouse TLX5 cells allografted in mouse assessed as increase in host survival time at 80 mg/kg relative to control1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID115851Activity against TLX-5 lymphoma in mice Percent increase in survival time at 5 mg/kg, 1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID119024survivors / total number of mice intracerebrally implanted leukemia L1210 at 30 mg/kg administered intraperitoneally on day 1 only. 4-5 day; 1/91980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID119137survivors / total number of mice intracerebrally implanted leukemia L1210 at 40 mg/kg administered intraperitoneally on day 1 only. 4-5 day; 10/101980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID15821Alkylating activity was determined1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
An analysis of 1-(2-chloroethyl)-1-nitrosourea activity at the cellular level.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1132747Drug metabolism in Wistar rat liver microsomes at 50 ug/ml after 5 mins1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1133737Toxicity in ip dosed BDF1 mouse1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis of analogues of N-(2-chloroethyl)-N'-(trans-4-methylcyclohexyl)-N-nitrosourea for evaluation as anticancer agents.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1132756Drug metabolism in Wistar rat liver microsomes assessed as total trans-4-OH CCNU level at 50 ug/ml after 10 mins by HPLC analysis1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID115847Activity against TLX-5 lymphoma in mice Percent increase in survival time at 10 mg/kg, 1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID1149432Antitumor activity against mouse advanced Lewis lung carcinoma allografted in BDF1 mouse assessed as disease cure at 50 mg/kg, ip administered as single dose on 7th day post-tumor implantation measured for 80 days post-drug treatment1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID115850Activity against TLX-5 lymphoma in mice Percent increase in survival time at 40 mg/kg, 1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1132758Antitumor activity against mouse TLX5 cells allografted in mouse assessed as increase in host survival time at 10 mg/kg relative to control1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID97586Antitumor activity against Leukemia L1210 cells in BDF1 mice at the dose of 50 mg/kg/day x 1 (i.p.), maximum increase in life-span1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
A new class of nitrosoureas. 4. Synthesis and antitumor activity of disaccharide derivatives of 3,3-disubstituted 1-(2-chloroethyl)-1-nitrosoureas.
AID15912Carbamoylating activity was determined1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
An analysis of 1-(2-chloroethyl)-1-nitrosourea activity at the cellular level.
AID1132745Antitumor activity against 0.25 ug/ml compound treated rat Walker 256 cells allografted in rat assessed as increase of host survival time cells incubated for 2 hrs with NADPH prior to animal injection1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID120328Number of day-60 survivors at the optimal dose of 32 mg/kg; 1/101984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Studies on synthesis and anticancer activity of selected N-(2-fluoroethyl)-N-nitrosoureas.
AID1132754Drug metabolism in Wistar rat liver microsomes assessed as total trans-3-OH CCNU level at 50 ug/ml after 10 mins by HPLC analysis1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID384312Neurotoxicity in ip dosed mouse by rotarod test2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
Design, synthesis and antiproliferative activity of some 3-benzylidene-2,3-dihydro-1-benzopyran-4-ones which display selective toxicity for malignant cells.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1149378Antitumor activity against mouse advanced Lewis lung carcinoma allografted in BDF1 mouse assessed as increase in host life span at 40 mg/kg, ip administered as single dose on 7th day post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1132743Antitumor activity against 1 ug/ml compound treated rat Walker 256 cells allografted in rat assessed as increase of host survival time cells incubated for 2 hrs with NADPH prior to animal injection1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID1132746Drug metabolism in Wistar rat liver microsomes at 50 ug/ml after 2.5 mins1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID1132755Drug metabolism in Wistar rat liver microsomes assessed as total cis-4-OH CCNU level at 50 ug/ml after 10 mins by HPLC analysis1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID409951Inhibition of human liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID66145Maximum effective dose required for antitumor activity against Ehrlich ascites carcinoma cells in male ICR mice.1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
A new class of nitrosoureas. 4. Synthesis and antitumor activity of disaccharide derivatives of 3,3-disubstituted 1-(2-chloroethyl)-1-nitrosoureas.
AID1123036Antitumor activity against rat 13762 cells allografted in Fischer/344 rat assessed as tumor growth inhibition at 10 mg/kg/day, sc for 10 days followed by double the dose every 2 days from day 11 to day 19 relative to vehicle-treated control1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Synthesis of steroidal nitrosoureas with antitumor activity.
AID116970Percent increase in life span was measured in mice intracerebrally implanted leukemia L1210 at 40 mg/kg administered intraperitoneally on day 1 only.1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1133738Antitumor activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as increase of life span of host measured up to 45 days1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis of analogues of N-(2-chloroethyl)-N'-(trans-4-methylcyclohexyl)-N-nitrosourea for evaluation as anticancer agents.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID115849Activity against TLX-5 lymphoma in mice Percent increase in survival time at 20 mg/kg, 1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Fluorinated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea: an attempt to control metabolism.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,826)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990997 (54.60)18.7374
1990's296 (16.21)18.2507
2000's238 (13.03)29.6817
2010's218 (11.94)24.3611
2020's77 (4.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 61.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index61.69 (24.57)
Research Supply Index7.81 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index112.82 (26.88)
Search Engine Supply Index2.07 (0.95)

This Compound (61.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials492 (24.91%)5.53%
Reviews142 (7.19%)6.00%
Case Studies154 (7.80%)4.05%
Observational1 (0.05%)0.25%
Other1,186 (60.05%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (90)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma) [NCT00031590]Phase 230 participants (Actual)Interventional2001-04-30Terminated(stopped due to The study was terminated prematurely due to slow accrual.)
A Phase II, Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma [NCT04863950]Phase 225 participants (Anticipated)Interventional2022-05-25Recruiting
Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma [NCT01290939]Phase 3592 participants (Actual)Interventional2011-10-31Completed
Phase II Study of Laser Interstitial Thermal Therapy (LITT) in Recurrent Glioblastoma [NCT03022578]Phase 27 participants (Actual)Interventional2017-11-07Terminated(stopped due to Slow accrual)
A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy [NCT02796261]Phase 3343 participants (Actual)Interventional2016-07-31Active, not recruiting
A Randomized, Control, Open-label, Multicenter, Phase II/III Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients [NCT03758014]Phase 2/Phase 3200 participants (Anticipated)Interventional2018-11-27Recruiting
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy [NCT04762069]Phase 2210 participants (Anticipated)Interventional2021-05-18Active, not recruiting
A Study to Evaluate the Safety and Efficacy of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression [NCT04573192]Phase 1/Phase 2142 participants (Anticipated)Interventional2021-02-19Recruiting
A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3) [NCT03149575]Phase 32 participants (Actual)Interventional2017-10-27Terminated(stopped due to Change in clinical development plan)
Randomized Phase II Trial of Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) In Adults With Recurrent Glioblastoma Multiforme [NCT01067469]Phase 283 participants (Actual)Interventional2010-01-31Completed
A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate Plus Lomustine Therapy Compared to Lomustine Monotherapy in Patients With Recurrent Glioblastoma [NCT01582269]Phase 2180 participants (Anticipated)Interventional2012-04-26Active, not recruiting
Improvement of Functional Outcome for Patients With Newly Diagnosed Grade II or III Glioma With Co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 Trial [NCT05331521]Phase 3406 participants (Anticipated)Interventional2021-04-07Recruiting
A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma and Reduced Therapy in Children With Medulloblastoma With Low-Risk Features [NCT05382338]Phase 3225 participants (Anticipated)Interventional2023-02-20Recruiting
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients [NCT02724579]Phase 245 participants (Anticipated)Interventional2017-11-17Recruiting
Phase III Trial of CCNU/Temozolomide (TMZ) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT-methylated Glioblastoma Patients [NCT01149109]Phase 3141 participants (Actual)Interventional2010-10-31Completed
A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma [NCT01562197]Phase 256 participants (Actual)Interventional2014-04-30Completed
AN INTERNATIONAL PROSPECTIVE TRIAL ON MEDULLOBLASTOMA (MB) IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH WNT BIOLOGICAL PROFILE (PNET 5 MB - LR and PNET 5 MB - WNT-HR), AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR), OR TP53 MUTATION, AND REGISTRY FOR MB OCCU [NCT02066220]Phase 2/Phase 3360 participants (Anticipated)Interventional2014-06-30Active, not recruiting
A Phase 1/2 Dose-escalation of USL311 as Single Agent and in Combination With Lomustine (CCNU) in Subjects With Advanced Solid Tumors, With Subsequent Single Agent and Combination Phase 2 Cohorts for Subjects With Relapsed/Recurrent Glioblastoma Multiform [NCT02765165]Phase 1/Phase 226 participants (Actual)Interventional2016-04-30Terminated(stopped due to Business reasons not related to safety)
A Single Arm Pilot Study to Evaluate the Safety and Feasibility of Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma [NCT05017610]Early Phase 10 participants (Actual)Interventional2021-10-20Withdrawn(stopped due to Per the PI-slow accrual)
A Phase II Study of Concurrent Radiation and Temozolomide Followed By Temozolomide and CCNU in the Treatment of Children With High-Grade Glioma [NCT00100802]Phase 2118 participants (Actual)Interventional2005-03-21Completed
INTELLANCE-2: ABT-414 Alone or ABT-414 Plus Temozolomide Versus Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group [NCT02343406]Phase 2266 participants (Actual)Interventional2015-02-17Completed
Treatment of Patients Over 65 Years With Primary CNS Lymphoma: High-dose Methotrexate Combined With Chemo-immunotherapy Followed by Maintenance Therapy [NCT00989352]Phase 256 participants (Anticipated)Interventional2009-09-30Recruiting
Safety and Efficacy of Liposomal Cytarabine in Combination With Radiotherapy (RT) and Lomustine for the Treatment of Leptomeningeal Metastasis From Malignant Melanoma [NCT01563614]Phase 11 participants (Actual)Interventional2012-03-31Terminated(stopped due to No patients can be recruited for this trial anymore due to other therapeutical approaches that became available.)
Randomized Phase II of Lomustine Versus Lomustine-Dasatinib in Patients With Recurrent Glioblastoma [NCT00948389]Phase 1/Phase 228 participants (Actual)Interventional2009-10-31Terminated(stopped due to Inability to meet protocol objectives)
A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone [NCT00777153]Phase 3423 participants (Actual)Interventional2008-10-31Completed
DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial [NCT02678975]Phase 2/Phase 388 participants (Actual)Interventional2017-01-31Completed
Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study. [NCT00761280]Phase 327 participants (Actual)Interventional2008-12-31Terminated(stopped due to Unable to recruit the projected patient number. All analyses are descriptive, only.)
Feasibility Study of a Static Magnetic and Electric Field Device in Adults With Recurrent Glioblastoma and Their Partners [NCT05410301]0 participants (Actual)Interventional2023-04-30Withdrawn(stopped due to PI leaving institution)
A Study to Evaluate the Safety and Efficacy of Different Administration Sequences of L19TNF in Combination With Lomustine in Patients With Glioblastoma at First Progression [NCT05304663]Phase 124 participants (Anticipated)Interventional2022-06-01Not yet recruiting
A Phase I Study of Temozolomide and CCNU in Pediatric Patients With Newly Diagnosed Incompletely Resected Non-Brainstem High-Grade Gliomas [NCT00006024]Phase 132 participants (Actual)Interventional2000-11-30Completed
Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI [NCT02843230]30 participants (Actual)Observational2016-08-01Completed
Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme [NCT01934361]Phase 135 participants (Actual)Interventional2014-02-28Completed
Randomized Phase 2 Clinical Trial of Repeated Intratumoral and Cervical Perilymphatic Lerapolturev Injections Versus Lomustine in Recurrent Glioblastoma (GBM) [NCT06177964]Phase 292 participants (Anticipated)Interventional2023-12-31Not yet recruiting
A Phase 1/2 Unblinded Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Lomustine for Bevacizumab-Naïve Adult Patients With Recurrent Malignant Glioma [NCT01989052]Phase 19 participants (Actual)Interventional2014-05-31Terminated(stopped due to This study was terminated early due to funding issues prior to completion of phase I)
Randomized Prospective Study of Adding Lomustine to Idarubicin and Cytarabine for Induction and Post-remission Chemotherapy in Older Patients With Acute Myeloid Leukaemia, and Feasibility of Allogeneic Transplantation for Patients From 60 to 65 Years Old [NCT00590837]Phase 3459 participants (Actual)Interventional2008-02-29Completed
A Phase III Trial of Gleostine® (Lomustine)-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma [NCT05095376]Phase 3306 participants (Anticipated)Interventional2021-11-29Recruiting
Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma [NCT00295815]Phase 3397 participants (Actual)Interventional2006-01-31Completed
Hyperfractionated Accelerated Radiotherapy (HART) With Chemotherapy (Cisplatin, CCNU, Vincristine) for Metastatic (M1-3) Medulloblastoma [NCT00276666]Phase 229 participants (Anticipated)Interventional2001-11-30Active, not recruiting
A Double-Blind, Placebo-Controlled, Randomised, Phase II Study Evaluating the Efficacy and Safety of Addition of Continuous Multiple Line Bevacizumab Treatment to Lomustine in Second (2nd)-Line Followed by Standard of Care (SOC) in Third (3rd)-Line and Be [NCT01860638]Phase 2296 participants (Actual)Interventional2013-08-19Completed
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma [NCT04421378]Phase 1/Phase 274 participants (Actual)Interventional2020-06-08Terminated(stopped due to Upon further consideration of the existing data and the competitive landscape, Karyopharm Therapeutics Inc has decided not to pursue the ongoing development of Selinexor in GBM at this time.)
Oral Combination Chemotherapy in the Treatment of AIDS-Associated Hodgkin's Disease [NCT00003114]Phase 25 participants (Actual)Interventional1997-07-31Completed
A Phase I, Open Label, Multi-Centre Study to Assess the Safety and Tolerability of Cediranib (RECENTIN™, AZD2171) in Combination With Lomustine Chemotherapy for Patients With Primary Recurrent Malignant Brain Tumours for Whom Lomustine Would be a Standard [NCT00503204]Phase 120 participants (Anticipated)Interventional2007-09-30Completed
A Phase I Study of Temozolomide, Thalidomide, and Lomustine (TTL) in Patients With Metastatic Melanoma in the Brain [NCT00527657]Phase 117 participants (Actual)Interventional2006-02-09Completed
A Pilot Study of Dose-Intensified Procarbazine, CCNU, Vincristine (PCV) for Poor Prognosis Pediatric and Adult Brain Tumors Utilizing Fibronectin-Assisted, Retroviral-Mediated Modification of CD34+ Peripheral Blood Cells With O6-Methylguanine DNA Methyltr [NCT00005796]Phase 110 participants (Actual)Interventional2000-02-29Completed
Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma [NCT00278278]Phase 3150 participants (Anticipated)Interventional2003-09-30Active, not recruiting
A Three-part, Phase I/II Dose-Escalation Study to Define the Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 With Subsequent Extension of Optimal Dose in Recurrent GBM Subjects [NCT03382977]Phase 1/Phase 298 participants (Anticipated)Interventional2017-12-06Recruiting
Randomized Prospective Study of Adding Lomustine to Idarubicin and Cytarabine for Induction Chemotherapy and Adding Intermediate Dose Cytarabine to Consolidation in Older Patients With Acute Myeloid Leukaemia [NCT00480064]Phase 3360 participants (Actual)Interventional1995-07-31Completed
Oral Combination Chemotherapy in Conjunction With G-CSF in the Treatment of Elderly Patients With Intermediate and High Grade Non-Hodgkin's Lymphoma [NCT00003113]Phase 26 participants (Actual)Interventional1997-07-31Terminated
Combination of 6-Thioguanine, Capecitabine, Celecoxib and Temozolomide or CCNU for Recurrent Anaplastic Glioma and Glioblastoma Multiforme [NCT00504660]Phase 275 participants (Actual)Interventional2003-09-30Completed
Multi-national, Open-label, Active-controlled, Randomized Dose-finding Study to Evaluate Efficacy of 2 Doses of AP 12009 in Recurrent Glioma, Administered Intratumorally as Continuous High-flow Microperfusion Over 7 Days Every Other Week [NCT00431561]Phase 2141 participants (Actual)Interventional2003-04-30Completed
A Prospective Randomised Controlled Trial Of Hyperfractionated Versus Conventionally Fractionated Radiotherapy In Standard Risk Medulloblastoma [NCT00053872]Phase 3316 participants (Anticipated)Interventional2003-02-28Active, not recruiting
Combination Chemotherapy (Methotrexate, Procarbazine And CCNU), Intraventricular Cytarabine And Methotrexate, +/- Intra-Ocular Chemotherapy For Patients With Primary Central Nervous System Lymphoma [NCT00074191]Phase 21 participants (Actual)Interventional2000-01-31Completed
A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV [NCT00052455]Phase 3500 participants (Anticipated)Interventional2002-10-31Completed
A Phase II Study of Temozolomide, Thalidomide, and Lomustine in the Treatment of Advanced Melanoma [NCT00072345]Phase 20 participants Interventional2003-07-31Completed
A Phase III, Randomized, Open-Label Study Of IV Edotecarin Vs Temozolomide Or Carmustine (BCNU) Or Lomustine (CCNU) In Patients With Glioblastoma Multiforme At First Relapse After Alkylator-Based (NEO) Adjuvant Chemotherapy [NCT00068952]Phase 3118 participants Interventional2003-08-31Completed
Dose-Modified Oral Combination Chemotherapy In Patients With Aids-Related Non-Hodgkin's Lymphoma In The United States And Africa [NCT00049439]Phase 254 participants (Actual)Interventional1998-03-31Completed
Hyperfractionated Accelerated Radiotherapy (HART) With Chemotherapy (Cisplatin, CCNU, Vincristine) for Non-Pineal Supratentorial Primitive Neuroectodermal Tumours [NCT00274911]Phase 230 participants (Anticipated)Interventional2004-02-29Active, not recruiting
Phase II Study of CCNU (Lomustine) in Patients With Advanced Non-Small Cell Lung Cancer and Aberrant Hypermethylation of the MGMT Gene [NCT00293280]Phase 242 participants (Anticipated)Interventional2005-07-31Completed
Multicenter Therapy Optimizing Study for Treatment of Children and Adolescents With Intracranial Medulloblastoma / PNET and Ependymoma [NCT00303810]567 participants (Actual)Interventional2001-01-31Completed
Phase 2 Clinical Trial of PC(Procarbazine-CCNU) Chemotherapy in Patients With Recurrent or Resistant Glioblastoma With Methylated MGMT [NCT01737346]Phase 252 participants (Anticipated)Interventional2012-10-31Recruiting
Phase 2 Trial of Indoximod With Chemotherapy and Radiation for Children With Progressive Brain Tumors or Newly Diagnosed DIPG [NCT04049669]Phase 2140 participants (Anticipated)Interventional2019-10-02Recruiting
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM [NCT03970447]Phase 2/Phase 31,030 participants (Anticipated)Interventional2019-07-30Recruiting
Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors [NCT03678883]Phase 2350 participants (Anticipated)Interventional2019-01-04Recruiting
Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old [NCT00002944]Phase 3428 participants (Actual)Interventional1997-04-30Completed
A Trial Of Radioimmunotherapy, Reduced-Dose External Beam Craniospinal Radiation Therapy With IMRT Boost, And Chemotherapy For Patients With Standard-Risk Medulloblastoma [NCT00058370]6 participants (Actual)Interventional2003-02-28Completed
PHASE II STUDY OF PREIRRADIATION PCV CHEMOTHERAPY IN PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMAS [NCT00002806]Phase 243 participants (Actual)Interventional1996-07-31Completed
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study [NCT05904119]Phase 3411 participants (Anticipated)Interventional2024-03-31Not yet recruiting
Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (PersoMed-I) [NCT04402073]Phase 2205 participants (Anticipated)Interventional2022-11-11Recruiting
Treatment Protocol for Relapsed Anaplastic Large Cell Lymphoma of Childhood and Adolescence [NCT00317408]96 participants (Anticipated)Interventional2004-04-30Active, not recruiting
Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas [NCT00002569]Phase 3299 participants (Actual)Interventional1994-07-31Completed
PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA [NCT00002840]Phase 3350 participants (Anticipated)Interventional1996-08-31Completed
Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors [NCT00003788]Phase 3270 participants (Anticipated)Interventional1998-04-30Active, not recruiting
Phase III Prospective Randomized Study of Craniospinal RT Followed by One of Two Adjuvant Chemotherapy Regimens (CCNU, CDDP, VCR OR CPM, CDDP, VCR) for Newly-Diagnosed Average Risk MedulloblastomaMEDULLOBLASTOMA [NCT00002875]Phase 3421 participants (Actual)Interventional1996-12-31Completed
A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial [NCT00085735]Phase 3549 participants (Actual)Interventional2004-04-30Active, not recruiting
A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma [NCT00003375]Phase 2/Phase 3370 participants (Actual)Interventional1998-10-31Completed
A Randomised Study Comparing CIDEX (CCNU, Oral Idarubicin and Dexamethasone) With Melphalan and Prednisolone in Relapsed Multiple Myeloma [NCT00003603]Phase 3660 participants (Anticipated)Interventional1998-03-31Active, not recruiting
Pilot Study Assessing the Feasibility of a Surgery and Chemotherapy-Only Approach in the Upfront Therapy of Children With Wnt Positive Standard Risk Medulloblastoma [NCT02212574]Early Phase 16 participants (Actual)Interventional2017-04-04Terminated(stopped due to Participant relapses led to abrupt stop of study.)
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma [NCT02414165]Phase 2/Phase 3403 participants (Actual)Interventional2015-11-30Terminated(stopped due to Sponsor Decision)
A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation [NCT02333513]100 participants (Anticipated)Interventional2015-02-28Not yet recruiting
A Phase 2, Open-label Study of ABI-009 (Nab-Rapamycin) in Patients With Recurrent High-grade Glioma and Patients With Newly Diagnosed Glioblastoma [NCT03463265]Phase 262 participants (Actual)Interventional2018-08-01Completed
Effect of Refnot on Immunity in Cancer Patients [NCT05898451]Phase 255 participants (Actual)Interventional2009-06-04Completed
A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer [NCT03425292]Phase 149 participants (Actual)Interventional2018-03-01Completed
Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy With Concomitant Antiretroviral Therapy in Patients With HIV-Associated Lymphoma in Sub-Saharan Africa [NCT01775475]Phase 27 participants (Actual)Interventional2016-09-15Completed
Regorafenib in Relapsed Glioblastoma REGOMA Study Randomized, Controlled Open-label Phase II Clinical Trial [NCT02926222]Phase 2119 participants (Actual)Interventional2015-11-30Completed
A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme: the STELLAR Study [NCT03025893]Phase 2/Phase 3100 participants (Anticipated)Interventional2018-08-31Recruiting
Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-methylated Glioblastoma: a Randomized Phase II Open Label Multicenter Study [NCT04933942]Phase 20 participants (Actual)Interventional2022-09-13Withdrawn(stopped due to Amgen withdrew interest in providing further financial support)
A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma [NCT00003101]Phase 260 participants (Anticipated)Interventional1997-08-31Completed
Combined Modality Therapy of AIDS-Related and Immunocompetent Primary CNS Lymphoma (PCL) Using Filgrastim (G-CSF) [NCT00003929]Phase 20 participants (Actual)Interventional1998-06-30Withdrawn
A Randomized, Open-label, Multicentric, Two-arm Pivotal Trial of SonoCloud-9 Combined With Carboplatin (CBDCA) vs Standard of Care Lomustine (CCNU) or Temozolomide (TMZ) in Patients Undergoing Planned Resection for First Recurrence Glioblastoma. [NCT05902169]Phase 3560 participants (Anticipated)Interventional2023-11-05Not yet recruiting
Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination With Lomustine in Patients With Recurrent Malignant Glioma [NCT01682187]Phase 166 participants (Actual)Interventional2005-12-15Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00031590 (1) [back to overview]Long Term Survival
NCT00085735 (22) [back to overview]Post-treatment Grade 3+ Hearing Loss as Measured by Common Terminology Criteria for Adverse Events (CTCAE) Version (v)4
NCT00085735 (22) [back to overview]Post-treatment Endocrine Function by CSI Group
NCT00085735 (22) [back to overview]Overall Survival (OS) by Molecular Subgroup Based on Methylation Arrays
NCT00085735 (22) [back to overview]Non-posterior Fossa (NPF) Failure Rate
NCT00085735 (22) [back to overview]Non-local Posterior Fossa (NLPF) Failure Rate
NCT00085735 (22) [back to overview]Post-treatment Neurocognitive Function as Measured by the Estimated Full-scale IQ (FSIQ) by CSI Group Within Time Window 3 (49 - 72 Months Post Diagnosis)
NCT00085735 (22) [back to overview]Incidence of Endocrine Dysfunction as Measured by Growth Hormone Stimulation Tests at the Time of Completion of Therapy by Radiotherapy (RT) Group
NCT00085735 (22) [back to overview]Progression-free Survival (PFS) by Molecular Subgroup Based on Methylation Arrays
NCT00085735 (22) [back to overview]Event-free Survival (EFS)
NCT00085735 (22) [back to overview]Event-free Survival (EFS)
NCT00085735 (22) [back to overview]Overall Survival (OS)
NCT00085735 (22) [back to overview]Local Posterior Fossa (LPF) Failure Rate
NCT00085735 (22) [back to overview]Incidence of Grade 3+ Hearing Loss at 1-year Post Treatment as Assessed by CTCAE v4
NCT00085735 (22) [back to overview]Overall Survival (OS)
NCT00085735 (22) [back to overview]Compliance Rates for All Eligible and Evaluable Patients Enrolled Within Time Window 3 (49 - 72 Months Post Diagnosis)
NCT00085735 (22) [back to overview]Compliance Rates for All Eligible and Evaluable Patients Enrolled Within Time Window 2 (27-48 Months Post Diagnosis)
NCT00085735 (22) [back to overview]Post-treatment Neurocognitive Function as Measured by the Estimated Full-scale IQ (FSIQ) by CSI Group Within Time Window 1 (4 - 15 Months Post Diagnosis).
NCT00085735 (22) [back to overview]Post-treatment Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) by CSI Group Within Time Window 1 (4-15 Months Post Diagnosis)
NCT00085735 (22) [back to overview]Compliance Rates for All Eligible and Evaluable Patients Enrolled Within Time Window 1 (4-15 Months Post Diagnosis)
NCT00085735 (22) [back to overview]Post-treatment Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) by CSI Group Within Time Window 2 (27-48 Months Post Diagnosis)
NCT00085735 (22) [back to overview]Post-treatment Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) by CSI Group Within Time Window 3 (49 - 72 Months Post Diagnosis)
NCT00085735 (22) [back to overview]Post-treatment Neurocognitive Function as Measured by the Estimated Full-scale IQ (FSIQ) by CSI Group Within Time Window 2 (27 - 48 Months Post Diagnosis)
NCT00100802 (2) [back to overview]Occurrence of Death Attributable to Complications of Protocol Therapy
NCT00100802 (2) [back to overview]One Year Overall Survival
NCT00504660 (2) [back to overview]12 Month-progression-free Survival for Participants With Anaplastic Tumors
NCT00504660 (2) [back to overview]6 Month Progression-free Survival for Participants With Glioblastoma
NCT00761280 (12) [back to overview]Disease Progression at 10, 12, 14, 16, 18, 21, and 24 Months by Independent Review in the Intent-to-treat Population - Number of Participants
NCT00761280 (12) [back to overview]Median Duration of Response (Days) by Independent Review (Descriptive Analysis, Only)
NCT00761280 (12) [back to overview]Median Overall Survival (Days) From Randomization in the Intent-to-treat Population (Descriptive Analysis, Only)
NCT00761280 (12) [back to overview]Median Time to Progression (Days) by Independent Review for the Intent-to-treat Population (Descriptive Analysis, Only)
NCT00761280 (12) [back to overview]Survival Rate at 24 Months in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)
NCT00761280 (12) [back to overview]Overall Response Rate (CR+PR) by Independent Review in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)
NCT00761280 (12) [back to overview]Tumor Control Rate (CR+PR+SD) by Independent Review in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)
NCT00761280 (12) [back to overview]Survival Rate at 12, 18, and 21 Months in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)
NCT00761280 (12) [back to overview]Survival at 24 Months in the Intent-to-treat Population - Number of Participants
NCT00761280 (12) [back to overview]Survival at 12, 18, and 21 Months in the Intent-to-treat Population - Number of Participants
NCT00761280 (12) [back to overview]Response Category by Independent Review in the Intent-to-treat Population - Number of Participants
NCT00761280 (12) [back to overview]Disease Progression Rate at 10, 12, 14, 16, 18, 21, and 24 Months by Independent Review in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)
NCT00777153 (6) [back to overview]Steroid Free Days
NCT00777153 (6) [back to overview]Alive and Progression Free Rate at 6 Months (APF6)
NCT00777153 (6) [back to overview]Daily Steroid Dose
NCT00777153 (6) [back to overview]Overall Survival (OS)
NCT00777153 (6) [back to overview]Progression Free Survival (PFS)
NCT00777153 (6) [back to overview]Response Rate
NCT00948389 (6) [back to overview]Number of Participants With Worst Grade of Hematological Toxicity Per NCI CTCAE Version 3.0 Criteria
NCT00948389 (6) [back to overview]Number of Participants With Dose-limiting Toxicities (DLTs)
NCT00948389 (6) [back to overview]Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs
NCT00948389 (6) [back to overview]Number of Participants With Worst Grade of Biochemistry Abnormality Per NCI CTCAE Version 3.0 Criteria
NCT00948389 (6) [back to overview]Number of Participants With Disease Progression at 12 Months
NCT00948389 (6) [back to overview]Deaths Within 30 Days of Protocol Treatment Discontinuation
NCT01067469 (5) [back to overview]Progression Free Survival (PFS)
NCT01067469 (5) [back to overview]Summary of Treatment Related Toxicities
NCT01067469 (5) [back to overview]Radiographic Response (RR)
NCT01067469 (5) [back to overview]Overall Survival (OS)
NCT01067469 (5) [back to overview]6-month Progression-free Survival (PFS-6)
NCT01775475 (8) [back to overview]Proportion of Patients Who Are Adherent to Chemotherapy
NCT01775475 (8) [back to overview]Change in Absolute CD4 Count From Baseline to Post-treatment
NCT01775475 (8) [back to overview]Number of Patients Who Complete Treatment
NCT01775475 (8) [back to overview]Overall Response Rate
NCT01775475 (8) [back to overview]Overall Survival
NCT01775475 (8) [back to overview]Participants Who Experienced an Adverse Event
NCT01775475 (8) [back to overview]Progression-free Survival
NCT01775475 (8) [back to overview]Proportion of Patients Who Are Adherent to Antiretroviral Therapy
NCT02343406 (11) [back to overview]Adult Study: Progression-Free Survival (PFS)
NCT02343406 (11) [back to overview]Adult Study: Overall Survival in the Subgroup With Epidermal Growth Factor Receptor (EGFRvIII) Mutation
NCT02343406 (11) [back to overview]Adult Study: Overall Survival (OS)
NCT02343406 (11) [back to overview]Pediatric Study: Percentage of Participants With Adverse Events From the First Visit Until 49 Days After the Last Dose of Study Drug
NCT02343406 (11) [back to overview]Pediatric Study: Maximum Observed Serum Concentration (Cmax) of ABT-414
NCT02343406 (11) [back to overview]Pediatric Study: Maximum Observed Plasma Concentration (Cmax) of Cys-mcMMAF
NCT02343406 (11) [back to overview]Pediatric Study: Half-life (t1/2) Observed for ABT-414
NCT02343406 (11) [back to overview]Pediatric Study: Area Under the Concentration-time-curve (AUC) Observed for Unconjugated Cys-mcMMAF
NCT02343406 (11) [back to overview]Pediatric Study: Area Under the Concentration-time Curve (AUC) Observed for ABT-414
NCT02343406 (11) [back to overview]Adult Study: Objective Response Rate (ORR)
NCT02343406 (11) [back to overview]Pediatric Study: Half-life (t1/2) Observed for Cys-mcMMAF
NCT02765165 (5) [back to overview]Area Under the Concentration Versus Time Curve (AUC)
NCT02765165 (5) [back to overview]Time to Peak Concentration (Tmax)
NCT02765165 (5) [back to overview]Phase 1: Maximum Tolerated Dose (MTD)
NCT02765165 (5) [back to overview]Phase 1: Maximum Tolerated Dose (MTD)
NCT02765165 (5) [back to overview]Peak Concentration (Cmax)
NCT03022578 (5) [back to overview]Number of Participants With Incidence of Toxicity (Significant Hemorrhage or Brain Herniation) Documented on Imaging
NCT03022578 (5) [back to overview]Length of Hospital Stay Following LITT
NCT03022578 (5) [back to overview]Disease Control Rate at 6 Months
NCT03022578 (5) [back to overview]Time to Progression (TTP)
NCT03022578 (5) [back to overview]Overall Survival (OS)
NCT03463265 (5) [back to overview]Median PFS
NCT03463265 (5) [back to overview]OS
NCT03463265 (5) [back to overview]OS at 12 Months
NCT03463265 (5) [back to overview]PFS Rate at 6 Months and 12 Months
NCT03463265 (5) [back to overview]ORR

Long Term Survival

"Survival Endpoints:~Event free survival and overall survival were assessed at 5 years from time of study enrollment" (NCT00031590)
Timeframe: Up to 5 years from date of randomization until the date of first documented progression or date of death from any cause, whichever came first.

InterventionPercentage of participants (Number)
5 year Overall Survival (OS)5 year Event Free Survival (EFS)
Study Treatment87.570

[back to top]

Post-treatment Grade 3+ Hearing Loss as Measured by Common Terminology Criteria for Adverse Events (CTCAE) Version (v)4

Proportions of patients with grade 3+ hearing loss after the completion of therapy will be calculated and reported separately for low dose craniospinal irradiation (LDCSI) versus (vs.) standard dose craniospinal irradiation (SDCSI) patients. Eligible and evaluable patients 3-7 years of age will be used. (NCT00085735)
Timeframe: Up to 3 years

InterventionPercentage of pts with g3+ hearing loss (Number)
Low-dose Craniospinal Radiation (LDSCI)11
Standard-dose Craniospinal Radiation (SDCSI)11

[back to top]

Post-treatment Endocrine Function by CSI Group

Post-treatment endocrine function was measured by laboratory assessment of the thyroid stimulating hormone (TSH). The mean TSH will be reported. (NCT00085735)
Timeframe: Up to 3 years

InterventionuU/ml (Mean)
Low-dose Craniospinal Radiation (LDSCI)5.3
Standard-dose Craniospinal Radiation (SDCSI)6.1

[back to top]

Overall Survival (OS) by Molecular Subgroup Based on Methylation Arrays

OS was defined as the time interval from date of study entry to date of death from any cause or to date of last contact for survivors. OS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% CI's. (NCT00085735)
Timeframe: 3 years

InterventionPercent probability of overall survival (Number)
Group 3 Medulloblastoma76.3
Group 4 Medulloblastoma97.3
Sonic Hedgehog (SHH) Medulloblastoma92.0
Wingless (WNT) Medulloblastoma98.3

[back to top]

Non-posterior Fossa (NPF) Failure Rate

NPF failure was defined as tumor recurrence within the neuroaxis but outside the radiation therapy clinical target volume (CTV). The cumulative incidence (CI) of NPF failure was estimated; 3-year estimates were reported with 95% confidence intervals. Patients with other failure types (e.g., LPF failure) and with other events prior to NPF failure (e.g., death, second malignancy) were considered as having competing events. (NCT00085735)
Timeframe: 3 years

InterventionPercentage of 3 yr cumulative incidence (Number)
Involved Field Radiation (IFRT)5.1
Posterior Fossa Radiation (PFRT)6.2

[back to top]

Non-local Posterior Fossa (NLPF) Failure Rate

NLPF failure was defined as tumor recurrence/progression outside the radiation therapy clinical target volume boost (CTV-boost) but within the posterior fossa CTV (CTV-PF). The cumulative incidence (CI) of NLPF failure was estimated; 3-year estimates were reported with 95% confidence intervals. Patients with other failure types (e.g., NPF, LPF) and with other events prior to NLPF failure (e.g., death, second malignancy) were considered as having competing events. (NCT00085735)
Timeframe: 3 years

InterventionPercentage of 3 yr cumulative incidence (Number)
Involved Field Radiation (IFRT)6.9
Posterior Fossa Radiation (PFRT)2.7

[back to top]

Post-treatment Neurocognitive Function as Measured by the Estimated Full-scale IQ (FSIQ) by CSI Group Within Time Window 3 (49 - 72 Months Post Diagnosis)

Post-treatment neurocognitive function was assessed. Full-scale IQ (FSIQ) is a representative measurement for neurocognitive function. FSIQ was measured by IQ tests. Assessments within the time window, from eligible and evaluable patients are reported. The time window is 49-72 months post diagnosis, only the assessments before progression date were reported. The Range of FSIQ is 50-150. A higher FSIQ is better. (NCT00085735)
Timeframe: 49 - 72 months post diagnosis

InterventionScores on a scale (Mean)
Low-dose Craniospinal Radiation (LDSCI)90.5
Standard-dose Craniospinal Radiation (SDCSI)86.4

[back to top]

Incidence of Endocrine Dysfunction as Measured by Growth Hormone Stimulation Tests at the Time of Completion of Therapy by Radiotherapy (RT) Group

Endocrine dysfunction was assessed by growth hormone stimulation (GHS) tests. We report the percentage of patients with abnormal growth hormone stimulation tests. (NCT00085735)
Timeframe: Post-treatment up to 3 years

InterventionPercentage of patients (Number)
Involved Field Radiation (IFRT)0.0
Posterior Fossa Radiation (PFRT)50.0

[back to top]

Progression-free Survival (PFS) by Molecular Subgroup Based on Methylation Arrays

PFS was defined as the time interval from date of study entry to disease progression, relapse or death due to cancer or to last follow-up. Second malignancies and deaths from causes clearly not associated with tumor progression or recurrence were censored. PFS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% CI's. (NCT00085735)
Timeframe: 3 years

InterventionPercentage probability of PFS (Number)
Group 3 Medulloblastoma70.6
Group 4 Medulloblastoma90.6
Sonic Hedgehog (SHH) Medulloblastoma90.4
Wingless (WNT) Medulloblastoma98.4

[back to top]

Event-free Survival (EFS)

EFS was defined as the time interval from date of study entry to date of disease progression, disease recurrence, second malignant neoplasm or death from any cause, whichever occurs first, or to the date of last follow-up for patients without events. EFS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% confidence intervals (CI's). (NCT00085735)
Timeframe: Assessed at 3 years

,
Interventionprobability of 3 year EFS (Number)
IFRT vs PFRT
Involved Field Radiation (IFRT)85.8
Posterior Fossa Radiation (PFRT)85.8

[back to top]

Event-free Survival (EFS)

EFS was defined as the time interval from date of study entry to date of disease progression, disease recurrence, second malignant neoplasm or death from any cause, whichever occurs first, or to the date of last follow-up for patients without events. EFS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% confidence intervals (CI's). (NCT00085735)
Timeframe: Assessed at 3 years

,
Interventionprobability of 3 year EFS (Number)
LDCSI vs SDCSI
Low-dose Craniospinal Radiation (LDSCI)76.3
Standard-dose Craniospinal Radiation (SDCSI)84.9

[back to top]

Overall Survival (OS)

OS was defined as the time interval from date of study entry to date of death from any cause or to the date of last follow-up for survivors. OS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% CI's. For purposes of this analysis, arms I, III and V (involved field radiation therapy [IFRT]) are combined and compared to arms II, IV and VI (posterior fossa irradiation [PFRT]). (NCT00085735)
Timeframe: 3 years

,
InterventionProbability of 3 yr OS rate (Number)
IFRT vs PFRT
Involved Field Radiation (IFRT)90.3
Posterior Fossa Radiation (PFRT)93.3

[back to top]

Local Posterior Fossa (LPF) Failure Rate

LPF failure was defined as tumor recurrence/progression within the tumor bed. The cumulative incidence (CI) of LPF failure was estimated; 3-year estimates were reported with 95% confidence intervals. Patients with other failure types (e.g., NPF) and with other events prior to LPF failure (e.g., death, second malignancy) were considered as having competing events. (NCT00085735)
Timeframe: 3 years

Interventionpercentage 3 yr cumulative incidence (Number)
Involved Field Radiation (IFRT)1.4
Posterior Fossa Radiation (PFRT)2.7

[back to top]

Incidence of Grade 3+ Hearing Loss at 1-year Post Treatment as Assessed by CTCAE v4

Proportions of patients with grade 3+ hearing impairment as assessed by CTCAE v4 at 1-year post treatment were calculated. (NCT00085735)
Timeframe: Up to 3 years

InterventionPercentage of pts with g3+ hearing loss (Number)
Involved Field Radiation (IFRT)8
Posterior Fossa Radiation (PFRT)8

[back to top]

Overall Survival (OS)

OS was defined as the time interval from date of study entry to date of death from any cause or to the date of last follow-up for survivors. OS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% CI's. For purposes of this analysis, arms I, III and V (involved field radiation therapy [IFRT]) are combined and compared to arms II, IV and VI (posterior fossa irradiation [PFRT]). (NCT00085735)
Timeframe: 3 years

,
InterventionProbability of 3 yr OS rate (Number)
LDCSI vs SDCSI
Low-dose Craniospinal Radiation (LDSCI)85.5
Standard-dose Craniospinal Radiation (SDCSI)90.4

[back to top]

Compliance Rates for All Eligible and Evaluable Patients Enrolled Within Time Window 3 (49 - 72 Months Post Diagnosis)

Compliance rates are calculated to monitor the compliance with long-term quality of life and functional status data submission. A patient will be compliant if the patient has metacognition index score. Compliance rates will be assessed at each of the 3 neurocognitive/quality of life assessment time windows. All eligible and evaluable patients enrolled will be used. Patients removed from treatment prior to the time of neuropsychological assessment (for reasons such as disease progression, death, withdrawal of consent, etc.) will not be included in the denominator to assess the compliance rate. The time window is 49 - 72 months post diagnosis. (NCT00085735)
Timeframe: 49 - 72 months post diagnosis

InterventionPercentage of Participants (Number)
Eligible and Evaluable Patients69

[back to top]

Compliance Rates for All Eligible and Evaluable Patients Enrolled Within Time Window 2 (27-48 Months Post Diagnosis)

Compliance rates are calculated to monitor the compliance with long-term quality of life and functional status data submission. A patient will be compliant if the patient has metacognition index score. Compliance rates will be assessed at each of the 3 neurocognitive/quality of life assessment time windows. All eligible and evaluable patients enrolled will be used. Patients removed from treatment prior to the time of neuropsychological assessment (for reasons such as disease progression, death, withdrawal of consent, etc.) will not be included in the denominator to assess the compliance rate. The time window is 27 - 48 months post diagnosis. (NCT00085735)
Timeframe: 27-48 months post diagnosis

InterventionPercentage of Participants (Number)
Eligible and Evaluable Patients32

[back to top]

Post-treatment Neurocognitive Function as Measured by the Estimated Full-scale IQ (FSIQ) by CSI Group Within Time Window 1 (4 - 15 Months Post Diagnosis).

Post-treatment neurocognitive function was assessed. Full-scale IQ (FSIQ) is a representative measurement for neurocognitive function. FSIQ was measured by IQ tests. Assessments within the time window, from eligible and evaluable patients are reported. The time window is 4-15 months post diagnosis, only the assessments before progression date were reported. The Range of FSIQ is 50-150. A higher FSIQ is better. (NCT00085735)
Timeframe: 4 -15 months post diagnosis

InterventionScores on a scale (Mean)
Low-dose Craniospinal Radiation (LDSCI)93.8
Standard-dose Craniospinal Radiation (SDCSI)96.2

[back to top]

Post-treatment Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) by CSI Group Within Time Window 1 (4-15 Months Post Diagnosis)

Metacognition index (MI) was measured by BRIEF test. Assessments within the time window, from eligible and evaluable patients are reported. If the patient had disease progression, only the assessments before progression date were reported. The MI is a standard T- score, and it ranges from 0 to 100. The higher score reported suggests a higher level of dysfunction. (NCT00085735)
Timeframe: 4 - 15 months post diagnosis

InterventionT-score (Mean)
Low-dose Craniospinal Radiation (LDSCI)50.7
Standard-dose Craniospinal Radiation (SDCSI)51.3

[back to top]

Compliance Rates for All Eligible and Evaluable Patients Enrolled Within Time Window 1 (4-15 Months Post Diagnosis)

Compliance rates are calculated to monitor the compliance with long-term quality of life and functional status data submission. A patient will be compliant if the patient has metacognition index score. Compliance rates will be assessed at each of the 3 neurocognitive/quality of life assessment time windows. All eligible and evaluable patients enrolled will be used. Patients removed from treatment prior to the time of neuropsychological assessment (for reasons such as disease progression, death, withdrawal of consent, etc.) will not be included in the denominator to assess the compliance rate. The time window is 4 - 15 months post diagnosis. (NCT00085735)
Timeframe: 4-15 months post diagnosis

InterventionPercentage of Participants (Number)
Eligible and Evaluable Patients58

[back to top]

Post-treatment Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) by CSI Group Within Time Window 2 (27-48 Months Post Diagnosis)

Metacognition index (MI) was measured by BRIEF test. Assessments within the time window, from eligible and evaluable patients are reported. If the patient had disease progression, only the assessments before progression date were reported. The MI is a standard T- score, and it ranges from 0 to 100. The higher score reported suggests a higher level of dysfunction. (NCT00085735)
Timeframe: 27-48 months post diagnosis

InterventionT-score (Mean)
Low-dose Craniospinal Radiation (LDSCI)51.4
Standard-dose Craniospinal Radiation (SDCSI)55.0

[back to top]

Post-treatment Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) by CSI Group Within Time Window 3 (49 - 72 Months Post Diagnosis)

Metacognition index (MI) was measured by BRIEF test. Assessments within the time window, from eligible and evaluable patients are reported. If the patient had disease progression, only the assessments before progression date were reported. The MI is a standard T- score, and it ranges from 0 to 100. The higher score reported suggests a higher level of dysfunction. (NCT00085735)
Timeframe: 49 - 72 months post diagnosis

InterventionT-score (Mean)
Low-dose Craniospinal Radiation (LDSCI)54.1
Standard-dose Craniospinal Radiation (SDCSI)58.6

[back to top]

Post-treatment Neurocognitive Function as Measured by the Estimated Full-scale IQ (FSIQ) by CSI Group Within Time Window 2 (27 - 48 Months Post Diagnosis)

Post-treatment neurocognitive function was assessed. Full-scale IQ (FSIQ) is a representative measurement for neurocognitive function. FSIQ was measured by IQ tests. Assessments within the time window, from eligible and evaluable patients are reported. The time window is 27-48 months post diagnosis, only the assessments before progression date were reported. The range of FSIQ is 50 - 150. A higher FSIQ is better. (NCT00085735)
Timeframe: 27 - 48 months post diagnosis

InterventionScores on a scale (Mean)
Low-dose Craniospinal Radiation (LDSCI)92.2
Standard-dose Craniospinal Radiation (SDCSI)90.5

[back to top]

Occurrence of Death Attributable to Complications of Protocol Therapy

Number of deaths due to complications of protocol therapy. (NCT00100802)
Timeframe: While receiving protocol therapy (up to 301 days excluding delays) or within 30 days of Termination of Protocol Therapy

Interventionpatients (Number)
Surgery, Chemoradiotherapy, Rest, Maintenance, FUP1

[back to top]

One Year Overall Survival

Estimated one year survival using the Kaplan-Meier methodology. (NCT00100802)
Timeframe: One year

InterventionEstimated probability (Number)
Surgery, Chemoradiotherapy, Rest, Maintenance, FUP0.7208

[back to top]

12 Month-progression-free Survival for Participants With Anaplastic Tumors

Progression-free Survival (PFS) at 12 months measured as percentage of participants that are alive and progression-free at 12 months (anaplastic tumors). A combination of neurological examination and MRI brain scan used to define overall response or progression. (NCT00504660)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Participants With Recurrent Anaplastic Glioma44

[back to top]

6 Month Progression-free Survival for Participants With Glioblastoma

Progression-free Survival (PFS) at 6 months measured as percentage of participants that are alive and progression-free at 6 months (glioblastoma multiforme). A combination of neurological examination and MRI brain scan used to define overall response or progression. (NCT00504660)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Participants With Glioblastoma Multiforme14

[back to top]

Disease Progression at 10, 12, 14, 16, 18, 21, and 24 Months by Independent Review in the Intent-to-treat Population - Number of Participants

"Tumor response was classified based on the (neuro-)radiologist's evaluation:~Complete Response (CR): Disappearance of all enhancing tumor on consecutive MRI scans at least 1 month apart, off steroids, neurologically stable or improved.~Partial Response (PR): ≥50% reduction in size of enhancing tumor on consecutive MRI scans at least 1 month apart, steroids stable or reduced, neurologically stable or improved.~Progressive Disease (PD): ≥25% increase in size of enhancing tumor or any new tumor on MRI scans, steroids stable or increased, neurologically worse.~Stable Disease (SD): all other situations.~Based on clinical and imaging data, an independent neuro-oncologist made the final assessment of Progressed versus Not Progressed. Participants who had MRI assessment results missing or unknown were UNK or missing, and were treated as Progressed for the purposes of the calculation." (NCT00761280)
Timeframe: 10, 12, 14, 16, 18, 21, and 24 months

,
Interventionparticipants (Number)
Progressed at 10 monthsNot progressed at 10 monthsStatus unknown / missing at 10 monthsLost to follow-up at 10 monthsProgressed at 12 monthsNot progressed at 12 monthsStatus unknown / missing at 12 monthsLost to follow-up at 12 monthsProgressed at 14 monthsNot progressed at 14 monthsStatus unknown / missing at 14 monthsLost to follow-up at 14 monthsProgressed at 16 monthsNot progressed at 16 monthsStatus unknown / missing at 16 monthsLost to follow-up at 16 monthsProgressed at 18 monthsNot progressed at 18 monthsStatus unknown / missing at 18 monthsLost to follow-up at 18 monthsProgressed at 21 monthsNot progressed at 21 monthsStatus unknown / missing at 21 monthsLost to follow-up at 21 monthsProgressed at 24 monthsNot progressed at 24 monthsStatus unknown / missing at 24 monthsLost to follow-up at 24 months
Chemotherapy5071507150715071507150715071
Trabedersen 10 µM7340725072507250725071607160

[back to top]

Median Duration of Response (Days) by Independent Review (Descriptive Analysis, Only)

"Duration of response was defined as the time from the first documentation of confirmed response (Complete Response, CR, or Partial Response, PR) to the first signs of Progressive Disease (PD), as assessed by the study neuro-oncologist. Median Duration of Response was calculated by Kaplan-Meier estimate.~Censoring rules were:~at the date of randomization -- participants without baseline assessments, or for those with no post-baseline timor assessments who were discontinued for other than progressive disease or death.~at the date of last tumor assessment -- discontinuation other than PD or death, or if a new treatment was started prior to disease progression~at the date of death or last tumor assessment -- death or PD after one missed tumor assessment~at the date of last tumor assessment -- death or PD after more than one missed tumor assessment~at the date of last tumor assessment -- participants on ongoing treatment at data cut-off" (NCT00761280)
Timeframe: Up to 24 months

Interventiondays (Median)
Trabedersen 10 µMNA
ChemotherapyNA

[back to top]

Median Overall Survival (Days) From Randomization in the Intent-to-treat Population (Descriptive Analysis, Only)

Median overall survival was defined as the date of randomization to the date of death. If a participant's status was unknown and there was no follow-up information available, they were categorized as 'Died' for the purposes of the analysis. Analysis was by Kaplan-Meier estimation. (NCT00761280)
Timeframe: Up to 24 months

Interventiondays (Median)
Trabedersen 10 µM458.0
Chemotherapy584.5

[back to top]

Median Time to Progression (Days) by Independent Review for the Intent-to-treat Population (Descriptive Analysis, Only)

Time to progression was calculated from the date of randomization to the date of the first documented tumor progression. Participants who did not progress or died were censored at the last tumor assessment date or the date of start of a new anti-tumor treatment or death. (NCT00761280)
Timeframe: Up to 24 months

Interventiondays (Median)
Trabedersen 10 µM57.0
Chemotherapy153.5

[back to top]

Survival Rate at 24 Months in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)

Survival rate was defined as the proportion of participants known to be alive at 24 months from randomization. If a participant's status was unknown and there was no follow-up information available, they were categorized as 'Died' for the purposes of the analysis. (NCT00761280)
Timeframe: 24 months

Interventionpercentage of participants (Number)
Trabedersen 10 µM28.6
Chemotherapy15.4

[back to top]

Overall Response Rate (CR+PR) by Independent Review in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)

Overall response rate was the proportion of participants with a best response of Complete Response (CR) or Partial Response (PR) observed from the start of treatment until disease progression. (NCT00761280)
Timeframe: Up to 24 months

Interventionpercentage of participants (Number)
Trabedersen 10 µM14.3
Chemotherapy7.7

[back to top]

Tumor Control Rate (CR+PR+SD) by Independent Review in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)

Tumor control rate was defined as the proportion of participants assessed as having Complete Response (CR), Partial Response (PR), or Stable Disease (SD). Participants with unknown or missing response were treated as non-responders. (NCT00761280)
Timeframe: Up to 24 months

Interventionpercentage of participants (Number)
Trabedersen 10 µM28.6
Chemotherapy53.8

[back to top]

Survival Rate at 12, 18, and 21 Months in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)

Survival rate was defined as the proportion of participants known to be alive at each time-point from randomization. Participants with unknown or missing status were considered treatment failures, i.e., assumed to be dead. (NCT00761280)
Timeframe: 12, 18, and 21 months

,
Interventionpercentage of participants (Number)
Survival rates at 12 monthsSurvival rates at 18 monthsSurvival rates at 21 months
Chemotherapy53.838.523.1
Trabedersen 10 µM57.142.935.7

[back to top]

Survival at 24 Months in the Intent-to-treat Population - Number of Participants

"Survival status was assessed at 24 months from randomization. Participants with unknown or missing status were considered treatment failures, i.e., assumed to be dead. The category Lost to / insufficient follow-up includes participants who were alive at last data collection point but did not yet have enough follow-up time to reach the 24 month time point." (NCT00761280)
Timeframe: 24 months

,
Interventionparticipants (Number)
AliveDiedLost to/insufficient follow-up
Chemotherapy256
Trabedersen 10 µM473

[back to top]

Survival at 12, 18, and 21 Months in the Intent-to-treat Population - Number of Participants

"Survival status was assessed at each time-point from randomization. Participants with unknown or missing status were considered treatment failures, i.e., assumed to be dead. The category Lost to follow-up for each time-point includes participants who were alive at the last data collection point but did not yet have enough follow-up time to reach the time point." (NCT00761280)
Timeframe: 12, 18, and 21 months

,
Interventionparticipants (Number)
Alive at 12 monthsDied at 12 monthsLost to follow-up at 12 monthsAlive at 18 monthsDied at 18 monthsLost to follow-up at 18 monthsAlive at 21 monthsDied at 21 monthsLost to follow-up at 21 months
Chemotherapy715535355
Trabedersen 10 µM851671572

[back to top]

Response Category by Independent Review in the Intent-to-treat Population - Number of Participants

"Tumor response was classified based on the (neuro-)radiologist's evaluation according to the Macdonald Response Criteria for bidimensionally measurable disease as outlined below:~Complete Response (CR): Disappearance of all enhancing tumor on consecutive MRI scans at least 1 month apart, off steroids, neurologically stable or improved.~Partial Response (PR): ≥50% reduction in size of enhancing tumor on consecutive MRI scans at least 1 month apart, steroids stable or reduced, neurologically stable or improved.~Progressive Disease (PD): ≥25% increase in size of enhancing tumor or any new tumor on MRI scans, steroids stable or increased, neurologically worse.~Stable Disease (SD): all other situations.~Two qualified neuro-radiologists reviewed scans at each MRI time point, with adjudication of discrepancies by a third reviewer. Their findings and clinical information were independently reviewed by a neuro-oncologist, who made the assessment of overall response." (NCT00761280)
Timeframe: Up to 24 months

,
Interventionparticipants (Number)
Complete Response (CR)Partial Response (PR)Stable Disease (SD)Progressive Disease (PD)UnknownMissing
Chemotherapy016132
Trabedersen 10 µM022712

[back to top]

Disease Progression Rate at 10, 12, 14, 16, 18, 21, and 24 Months by Independent Review in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)

"Tumor response was classified based on the (neuro-)radiologist's evaluation:~Complete Response (CR): Disappearance of all enhancing tumor on consecutive MRI scans at least 1 month apart, off steroids, neurologically stable or improved.~Partial Response (PR): ≥50% reduction in size of enhancing tumor on consecutive MRI scans at least 1 month apart, steroids stable or reduced, neurologically stable or improved.~Progressive Disease (PD): ≥25% increase in size of enhancing tumor or any new tumor on MRI scans, steroids stable or increased, neurologically worse.~Stable Disease (SD): all other situations.~Based on clinical and imaging data, an independent neuro-oncologist made the final assessment of Progressed versus Not Progressed. Participants who had MRI assessment results missing or unknown were UNK or missing, and were treated as Progressed for the purposes of the calculation." (NCT00761280)
Timeframe: 10, 12, 14, 16, 18, 21 and 24 months

,
Interventionpercentage of participants (Number)
Progression rate at 10 monthsProgression rate at 12 monthsProgression rate at 14 monthsProgression rate at 16 monthsProgression rate at 18 monthsProgression rate at 21 monthsProgression rate at 24 months
Chemotherapy100.0100.0100.0100.0100.0100.0100.0
Trabedersen 10 µM78.685.785.785.785.792.992.9

[back to top]

Steroid Free Days

Number of days known not to have used any steroids prior to progression (NCT00777153)
Timeframe: Baseline to the date of first documented progression or date of death or study discontinuation, whichever came first, assessed up to 2014-April-25

InterventionDays (Mean)
Cediranib 30mg75.8
Cediranib 20mg + Lomustine 119mg74.8
Lomustine 110mg92.3

[back to top]

Alive and Progression Free Rate at 6 Months (APF6)

Proportion of patients alive and progression free at 6 months (based on central review) as estimated from Kaplan-Meier techniques. Values are percentages. (NCT00777153)
Timeframe: 6 Months

Intervention% of patients alive and progression free (Number)
Cediranib 30mg16.2
Cediranib 20mg + Lomustine 100mg34.5
Lomustine 100mg24.5

[back to top]

Daily Steroid Dose

The mean steroid dosage prior to treatment will be considered as the patient's baseline. The percent change in average daily steroid dosage from baseline is calculated by following formula: PC = (md - bm)/bm*100; where PC is the percent change in average daily steroid dosage from baseline; md the mean daily steroid dosage recorded from the first day of therapy to progression; and bm the baseline mean. (NCT00777153)
Timeframe: Baseline to the date of first documented progression or date of death or study discontinuation, whichever came first, assed up to 2014-April-25

Interventionpercentage of change (Number)
Cediranib 30mg-17.6
Cediranib 20mg + Lomustine 110mg-1.8
Lomustine 110mg36.6

[back to top]

Overall Survival (OS)

Number of months from randomisation to the date of death from any cause (NCT00777153)
Timeframe: Baseline through to date of death up to 25th April 2010

InterventionMonths (Median)
Cediranib 30mg8.0
Cediranib 20mg + Lomustine 110mg9.4
Lomustine 110mg9.8

[back to top]

Progression Free Survival (PFS)

"For patients with measurable disease at entry (at least one lesion that has a shortest diameter~≥10 mm at baseline on 2 axial slices), PFS will be defined as the earliest time that:~The sum of the products of the largest perpendicular diameters of contrast enhancement for all lesions has increased by a greater than or equal to 25% in comparison to the nadir scan as long as the shortest diameter is ≥15 mm. If the dose of steroids has been reduced within the 10 days prior to the scan being conducted, progression will be based on a follow-up scan performed after the dose of steroids has been stabilized for 10 days.~The patient has died from any cause.~A new lesion is detected that is outside the original tumor volume and has a shortest diameter ≥10 mm." (NCT00777153)
Timeframe: Baseline at 6 weeks and then every 6 weeks to discontinuation

InterventionDays (Median)
Cediranib 30mg92
Cediranib 20mg+ Lomustine 110mg125
Lomustine 110mg82

[back to top]

Response Rate

"An individual visit response of PR was defined as a greater than or equal to 50% reduction in the sum of the products of the largest perpendicular diameters of contrast enhancement for all lesions compared to baseline as long as the steroid dose has not been increased within the previous 10 days and no new lesions are present.~An individual visit response of CR was defined as the complete disappearance of all tumor on MRI scan." (NCT00777153)
Timeframe: Baseline at 6 weeks and then every 6 weeks to discontinuation

InterventionParticipants (Number)
Cediranib 30mg18
Cediranib 20mg + Lomustine 110mg21
Lomustine 110mg5

[back to top]

Number of Participants With Worst Grade of Hematological Toxicity Per NCI CTCAE Version 3.0 Criteria

Neutrophils (neutropenia): Grade (gr)1 NCT00948389)
Timeframe: Assessed at baseline, every 2 weeks during cycles 1-6 (6-week cycles), and every 6 weeks after cycle 6. Median number of cycles = 1.0 (range: 1.0 - 7.0).

,,,,
Interventionparticipants (Number)
At least 1 Grade 1-4 NeutropeniaAt least 1 Grade 1-4 LeukopeniaAt least 1 Grade 1-4 LymphocytopeniaAt least 1 Grade 1-4 ThrombocytopeniaAt least 1 Grade 1-4 AnemiaAt least 1 Grade 3-4 NeutropeniaAt least 1 Grade 3-4 LeukopeniaAt least 1 Grade 3-4 LymphocytopeniaAt least 1 Grade 3-4 ThrombocytopeniaAt least 1 Grade 3-4 Anemia
Dasatinib, 100 mg BID + Lomustine, 90 mg/m^22446600121
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^23556621440
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^22323111000
Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^20001000000
Dasatinib, 150 mg/d + Lomustine, 90 mg/m^25699944550

[back to top]

Number of Participants With Dose-limiting Toxicities (DLTs)

Grades (gr) according to National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE), version 3.0. DLTs were defined as adverse drug reactions as follows: absolute neutrophil counts <0.5x10^9/L (gr4) lasting for 7 consecutive days; febrile neutropenia (neutrophil count <1x10^9/L and fever of >=38.5°C); thrombocytopenia (gr4); any gr3/4 nonhematological toxicity except nausea, vomiting and fever which could be rapidly controlled with appropriate measures; any toxicity which did not allow administering at least 70% of the intended dose intensity for both agents. (NCT00948389)
Timeframe: The duration for observation of DLT was 2 6-week cycles in participants with escalated dose (QD to BID) and 1 6 -week cycle for participants starting with BID regime. For participants receiving dasatinib at 150 mg, DLTs were only documented over cycle 1.

Interventionparticipants (Number)
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^23
Dasatinib, 100 mg BID + Lomustine, 90 mg/m^23
Dasatinib, 150 mg/d + Lomustine, 90 mg/m^24

[back to top]

Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs

SAE=any untoward medical event that results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires inpatient hospitalization or prolongation. AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Treatment-related(Tx-R)=certainly, probably, possibly related and unknown relationship to study drug. AE grades(Gr) 1=Mild; 2=Moderate; 3=Severe; 4=Life-threatening. (NCT00948389)
Timeframe: Assessed at baseline, every 2 weeks during cycles 1-6 (6-week cycles), and every 6 weeks after cycle 6. Median number of cycles = 1.0 (range: 1.0 - 7.0).

,,,,
Interventionparticipants (Number)
Deaths within 30 days of Tx DiscontinuationTx-R Deaths within 30 days of Tx DiscontinuationAt Least 1 SAEAt Least 1 Tx-R SAEDiscontinuations Due to AEsAt Least 1 AEAt Least 1 Gr 3/4 AEAt Least 1 Tx-R AEAt Least 1 Tx-R Gr 3/4 AE
Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2104107450
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2105436250
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2001003220
Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2000001010
Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2004119470

[back to top]

Number of Participants With Worst Grade of Biochemistry Abnormality Per NCI CTCAE Version 3.0 Criteria

Grades (gr) 1=mild; gr2=moderate; gr3=severe; gr4=life-threatening. For details of NCI CTCAE laboratory values for each grade, please refer to http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_30. Low Potassium=Hypokalemia, High Potassium=Hyperkalemia, Low Sodium=Hyponatremia, Low Calcium=Hypocalcemia, High Bilirubin=Hyperbilirubinemia, low phosphatase=Hypophosphatemia, Low Potassium=Hypokalemia. (NCT00948389)
Timeframe: Assessed at baseline, every 2 weeks during cycles 1-6 (6-week cycles), and every 6 weeks after 6 cycles. Median number of cycles = 1.0 (range: 1.0 - 7.0).

,,,,
Interventionparticipants (Number)
At least 1 Gr 1-4 HypokalemiaAt least 1 Gr 1-4 HyperkalemiaAt least 1 Gr 1-4 HyponatremiaAt least 1 Gr 1-4 HypernatremiaAt least 1 Gr 1-4 CreatinineAt least 1 Gr 1-4 HypocalcemiaAt least 1 Gr1-4 HyperbilirubinemiaAt least 1 Gr 1-4 Aspartate Aminotransferase / ASTAt least 1 Gr 1-4 HypophosphatemiaAt least 1 Gr 3-4 Hypokalemia
Dasatinib, 100 mg BID + Lomustine, 90 mg/m^21000030410
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^21011030210
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^20101210010
Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^20000001000
Dasatinib, 150 mg/d + Lomustine, 90 mg/m^23005020631

[back to top]

Number of Participants With Disease Progression at 12 Months

As measured by brain magnetic resonance imaging. (NCT00948389)
Timeframe: 12 months

Interventionparticipants (Number)
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^26
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^23
Dasatinib, 100 mg BID + Lomustine, 90 mg/m^27
Dasatinib, 150 mg/d + Lomustine, 90 mg/m^29
Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^21

[back to top]

Deaths Within 30 Days of Protocol Treatment Discontinuation

(NCT00948389)
Timeframe: From time of randomization through within 30 days after protocol treatment discontinuation. Median (full range) number of 6-week treatment cycles was 1.0 (1.0-7.0).

Interventionparticipants (Number)
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^21
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^20
Dasatinib, 100 mg BID + Lomustine, 90 mg/m^21
Dasatinib, 150 mg/d + Lomustine, 90 mg/m^20
Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^20

[back to top]

Progression Free Survival (PFS)

Participants with no disease progression as measured by magnetic resonance imaging (MRI) scans. Participants followed by MRI scans, as used for baseline tumor measurements, and removed from study if progression is documented after any cycle of treatment. PFS determined from date of registration in the trial and not date of randomization into chemotherapy arms (i.e. after surgery for resection of recurrent tumor). (NCT01067469)
Timeframe: Documented from the date of registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year

Interventionmonths (Median)
Standard Dose Bevacizumab4.11
Low Dose Bevacizumab + Lomustine4.34

[back to top] [back to top]

Radiographic Response (RR)

Definition of Modified Radiographic Response Assessment Criteria for Glioblastoma (GBM) . Complete, Partial, Progressive Disease and Stable Disease. Radiographic response determined in comparison to the tumor measurements obtained at baseline (post-radiation scan will be baseline for newly diagnosed GBM and pre-treatment scans will be the baseline for recurrent GBM) for determination of response, and the smallest tumor measurement at either pre-treatment baseline or following initiation of therapy for determining progression. (NCT01067469)
Timeframe: One year

,
InterventionParticipants (Count of Participants)
Complete ResponsePartial ResponseProgressive DiseaseStable Disease
Low Dose Bevacizumab + Lomustine03919
Standard Dose Bevacizumab0111113

[back to top]

Overall Survival (OS)

Overall Survival(OS) is defined: Time of presentation to date of death or censored at last follow-up date (NCT01067469)
Timeframe: through study completion, an average of 2 years

InterventionMonths (Median)
Standard Dose Bevacizumab8.3
Low Dose Bevacizumab + Lomustine9.6

[back to top]

6-month Progression-free Survival (PFS-6)

Participants with no disease progression as measured by magnetic resonance imaging (MRI) scans. Participants followed by MRI scans, as used for baseline tumor measurements, and removed from study if progression is documented after any cycle of treatment. PFS determined from date of registration in the trial and not date of randomization into chemotherapy arms (i.e. after surgery for resection of recurrent tumor). (NCT01067469)
Timeframe: 6 Months

Interventionpercentage of participants (Number)
Standard Dose Bevacizumab23.6
Low Dose Bevacizumab + Lomustine36.4

[back to top]

Proportion of Patients Who Are Adherent to Chemotherapy

Patients who did not miss any doses of chemotherapy (NCT01775475)
Timeframe: Up to 18 weeks

InterventionParticipants (Count of Participants)
Arm I (CHOP)4
Arm II (Oral Chemotherapy)3

[back to top]

Change in Absolute CD4 Count From Baseline to Post-treatment

Change in absolute CD4 count from baseline to post-treatment (visit 6) (NCT01775475)
Timeframe: From baseline to 18 weeks

Interventioncells per mm^3 (Mean)
Arm I (CHOP)-41.3
Arm II (Oral Chemotherapy)203.3

[back to top]

Number of Patients Who Complete Treatment

Number of patients who complete chemotherapy treatment. (NCT01775475)
Timeframe: Up to 18 weeks

InterventionParticipants (Count of Participants)
Arm I (CHOP)3
Arm II (Oral Chemotherapy)1

[back to top]

Overall Response Rate

Overall response is complete or partial response as defined by response definitions of the 2014 International Conference on Malignant Lymphoma Imaging Working Group (i.e. Lugano classification). Complete response is the disappearance of all lesions with no new lesions detected. Partial response is >=50% decrease in the sum of the perpendicular diameters of up to 6 target measurable nodes and extranodal sites and no new sites of disease. (NCT01775475)
Timeframe: Up to 24 months

InterventionParticipants (Count of Participants)
Arm I (CHOP)3
Arm II (Oral Chemotherapy)1

[back to top]

Overall Survival

Proportion of participants who survived 2 years (NCT01775475)
Timeframe: Up to 24 months

InterventionProportion of participants (Number)
Arm I (CHOP)0
Arm II (Oral Chemotherapy)0

[back to top]

Participants Who Experienced an Adverse Event

Number of participants who experienced an adverse event (NCT01775475)
Timeframe: Up to 24 months

InterventionParticipants (Count of Participants)
Arm I (CHOP)4
Arm II (Oral Chemotherapy)3

[back to top]

Progression-free Survival

Proportion of participants who survived without disease progression at 2 years (NCT01775475)
Timeframe: Up to 24 months

Interventionproportion (Number)
Arm I (CHOP)0
Arm II (Oral Chemotherapy)0

[back to top]

Proportion of Patients Who Are Adherent to Antiretroviral Therapy

Number of patients who did not miss any of their doses of antiretroviral therapy (NCT01775475)
Timeframe: Up to 24 months

InterventionParticipants (Count of Participants)
Arm I (CHOP)3
Arm II (Oral Chemotherapy)3

[back to top]

Adult Study: Progression-Free Survival (PFS)

Progression-free survival was assessed per response assessment in neuro-oncology criteria (RANO) criteria and assessed by an independent review committee and was defined as the length of time during and after the treatment of a disease, that the participant lived with the disease but did not get worse. (NCT02343406)
Timeframe: Measured every 8 weeks from date of randomization until the date of first objective progression or subject's death, whichever occurred first, up to 2 years

,,
Interventionmonths (Number)
25th quartile50th quartile75th quartile
ABT-414_adult1.51.93.5
ABT-414/Temozolomide1.82.74.9
Control (Temozolomide/Lomustine)1.61.94.2

[back to top]

Adult Study: Overall Survival in the Subgroup With Epidermal Growth Factor Receptor (EGFRvIII) Mutation

Overall Survival (OS) was defined as time from randomization to death due to any cause, regardless of whether the event occurred on or off study drug (depatuxizumab mafodotin/temozolomide/lomustine) for all randomized participants that had the Epidermal Growth Factor Receptor (EGFRvIII) mutation. (NCT02343406)
Timeframe: From the date of randomization up to the date of participant's death; participants who completed treatment were to be assessed every 12 weeks, up to 28 months

,,
Interventionmonths (Number)
25th quartile50th quartile75th quartile
ABT-414_adult5.08.413.9
ABT-414/Temozolomide6.39.414.4
Control (Temozolomide/Lomustine)4.77.512.4

[back to top]

Adult Study: Overall Survival (OS)

Overall Survival (OS) was defined as time from randomization to death due to any cause, regardless of whether the event occurred on or off study drug (depatuxizumab mafodotin/temozolomide/lomustine). (NCT02343406)
Timeframe: From the date of randomization up to the date of participant's death; participants who completed treatment were to be assessed every 12 weeks, up to 28 months.

,,
Interventionmonths (Number)
25th quartile50th quartile75th quartile
ABT-414_adult4.67.915.5
ABT-414/Temozolomide5.79.616.9
Control (Temozolomide/Lomustine)4.98.212.6

[back to top]

Pediatric Study: Percentage of Participants With Adverse Events From the First Visit Until 49 Days After the Last Dose of Study Drug

The severity of each adverse event was rated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE Version 4.0) (NCT02343406)
Timeframe: From participant's first visit until 49 days after the participant's last dose of study drug, up to 63 weeks

Interventionpercentage of participants (Number)
ABT-414_ Pediatric100

[back to top]

Pediatric Study: Maximum Observed Serum Concentration (Cmax) of ABT-414

Cmax is the peak concentration that a drug achieves in a specified compartment after the drug has been administrated and before administration of a second dose. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2,3,5,8,15; Cycle 2 Day 1; Cycle 3 Day 1; Cycle 5 Day 1; Day 1 of every two cycles starting with Cycle 5; and 35 days after the last dose

Interventionµg/mL (Mean)
ABT-414_ Pediatric31.4

[back to top]

Pediatric Study: Maximum Observed Plasma Concentration (Cmax) of Cys-mcMMAF

Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose. Cys-mcMMAF is a toxic metabolite of depatuxizumab mafodotin. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2, 3, 5, 8

Interventionng/mL (Mean)
ABT-414_ Pediatric0.272

[back to top]

Pediatric Study: Half-life (t1/2) Observed for ABT-414

Half-life is the calculated time it takes for half of the drug to leave the body. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2,3,5,8,15; Cycle 2 Day 1; Cycle 3 Day 1; Cycle 5 Day 1; Day 1 of every two cycles starting with Cycle 5; and 35 days after the last dose

Interventiondays (Mean)
ABT-414_ Pediatric9.0

[back to top]

Pediatric Study: Area Under the Concentration-time-curve (AUC) Observed for Unconjugated Cys-mcMMAF

AUC is a measure of how long and how much drug or drug metabolite is present in the body after dosing. The AUC of Cys-mcMMAF, a toxic metabolite of depatuxizumab mafodotin, in the pediatric population was measured following treatment to confirm that this was comparable to adults, and that the dosing levels are appropriate for a pediatric population. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2, 3, 5, 8

Interventionng*h/mL (Mean)
ABT-414_ Pediatric14.1

[back to top]

Pediatric Study: Area Under the Concentration-time Curve (AUC) Observed for ABT-414

AUC is a measure of how long and how much drug is present in the body after dosing. The AUC of depatuxizumab mafodotin (ABT-414) in the pediatric population was measured following treatment to confirm that this was comparable to adults, and that the dosing levels are appropriate for a pediatric population. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2,3,5,8,15; Cycle 2 Day 1; Cycle 3 Day 1; Cycle 5 Day 1; Day 1 of every two cycles starting with Cycle 5; and 35 days after the last dose

Interventionµg*h/mL (Mean)
ABT-414_ Pediatric3170

[back to top]

Adult Study: Objective Response Rate (ORR)

The objective response rate (ORR) included best overall responses - complete response (CR) and partial response (PR) - assessed by the independent review committee per response assessment in neurooncology criteria (RANO) criteria from the date of randomization until disease progression or death, whichever came first. All objective responses (CR and PR) must be have been confirmed by repeat MRI 4 weeks after the first time when CR or PR is identified. Any subject who did not meet CR or PR including those who did not have post-baseline radiological assessments was considered a nonresponder. (NCT02343406)
Timeframe: Every 8 weeks at each assessment of disease, up to 28 months

Interventionpercentage of participants (Number)
ABT-414/Temozolomide14.3
ABT-414_adult7.7
Control (Temozolomide/Lomustine)4.4

[back to top]

Pediatric Study: Half-life (t1/2) Observed for Cys-mcMMAF

Half-life is the calculated time it takes for half of the drug or drug metabolite to leave the body. CysmcMMAF is a toxic metabolite of depatuxizumab mafodotin. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2, 3, 5, 8

Interventiondays (Mean)
ABT-414_ Pediatric11.2

[back to top]

Area Under the Concentration Versus Time Curve (AUC)

Area under the curve versus time from time 0 to infinity for USL311 concentration in plasma (NCT02765165)
Timeframe: Day 1

Interventionng*h/mL (Geometric Mean)
Part 1a, Cohort 1181
Part 1a, Cohort 2437
Part 1a, Cohort 3a711
Part 1a, Cohort 3b1193
Part 1a, Cohort 41059
Part 1b, Cohort 15.95
Part 1b, Cohort 216.4
Part 1b, Cohort 330.4

[back to top]

Time to Peak Concentration (Tmax)

Time to peak concentration of USL311 in plasma (NCT02765165)
Timeframe: Day 1

InterventionHours (Median)
Part 1a, Cohort 11.05
Part 1a, Cohort 21.04
Part 1a, Cohort 3a0.53
Part 1a, Cohort 3b2.28
Part 1a, Cohort 42.55
Part 1b, Cohort 10.63
Part 1b, Cohort 20.67
Part 1b, Cohort 30.565

[back to top]

Phase 1: Maximum Tolerated Dose (MTD)

The MTD was defined as the highest safe dose (mg/m^2) administered where safe is defined by having at least a 50% probability that the dose limiting toxicity (DLT) rate is less than 33%, as determined by a modified continuous reassessment model. (NCT02765165)
Timeframe: Assessed weekly during treatment period. Median duration of exposure was 5.14 (range 2.1-17.3) weeks.

Interventionmg/m^2 (Number)
Part 1a, Dose-escalation, All Oral CohortsNA

[back to top]

Phase 1: Maximum Tolerated Dose (MTD)

The MTD was defined as the highest safe dose (mg) administered where safe is defined by having at least a 50% probability that the dose limiting toxicity (DLT) rate is less than 33%, as determined by a modified continuous reassessment model. (NCT02765165)
Timeframe: Assessed weekly during treatment period. Median duration of exposure was 6.00 (range 0.3-30.0) weeks.

Interventionmg (Number)
Part 1b, Dose-escalation, All Oral CohortsNA

[back to top]

Peak Concentration (Cmax)

Peak USL311 concentration (Cmax) in plasma (NCT02765165)
Timeframe: Day 1

Interventionng/mL (Geometric Mean)
Part 1a, Cohort 148.2
Part 1a, Cohort 269.1
Part 1a, Cohort 3a200
Part 1a, Cohort 3b168
Part 1a, Cohort 4107
Part 1b, Cohort 12.06
Part 1b, Cohort 24.74
Part 1b, Cohort 36.68

[back to top]

Number of Participants With Incidence of Toxicity (Significant Hemorrhage or Brain Herniation) Documented on Imaging

Safety and toxicity of LITT by determination of adverse events and surgical complications within 2 weeks of the procedure, plus an additional 4 weeks (to account for potential delayed inflammatory changes and initiation of subsequent treatment). Safety for LITT procedure will be defined as the absence of severe clinical toxicity as determined by the CTCAE version 4.0, within 6 weeks of the procedure, and/or absence of acute events (ie, significant hemorrhage or brain herniation) documented on imaging. Severe toxicity will also be defined as a drop of 20 points or more in KPS and not amenable to corticosteroids, and likely attributable to the procedure, or symptomatic hemorrhage, increased brain edema resulting in herniation/impending herniation, and/or significant neurologic decline not amenable to corticosteroids. Safety and toxicity will be reassessed again throughout the duration of the study. (NCT03022578)
Timeframe: approximately 3 years 3 months

InterventionParticipants (Count of Participants)
Treatment (LITT, Lomustine)0

[back to top]

Length of Hospital Stay Following LITT

The length of hospital stay in days, weeks or months. Length of Hospital stay was summarized by using standard descriptive statistics, such as mean, standard deviation, median, and range for continuous variables, frequency and proportion for categorical variables. (NCT03022578)
Timeframe: approximately 3 years 3 months

Interventiondays (Median)
Treatment (LITT, Lomustine)3

[back to top]

Disease Control Rate at 6 Months

"Stable Disease per RANO occurs if the patient does not qualify for response or progression and requires stable non enhancing lesions, same/lower dose of corticosteroids, and clinical stability.~Complete Response per RANO requires complete disappearance of all enhancing measurable and nonmeasurable disease for at least 4 weeks; no new lesions; and stable/improved nonenhancing lesions, off corticosteroids (or on physiologic replacement dose) and clinical improvement/stability. Partial Response per RANO requires ≥50% decrease of enhancing lesions compared with baseline, sustained for at least 4 weeks; no progression of nonmeasurable disease; no new lesions; stable/improved nonenhancing lesions, same/lower dose of corticosteroids not greater than the dose at time of the baseline scan and clinically improved/stable." (NCT03022578)
Timeframe: At 6 months

InterventionParticipants (Count of Participants)
Progression DiseasePartial ResponseNon Evaluable
Treatment (LITT, Lomustine)211

[back to top]

Time to Progression (TTP)

Progression disease per the Response Assessment in Neuro-Oncology (RANO) is defined by any of the following: ≥25% increase in the sum of the products of perpendicular diameters of enhancing lesions (compared with baseline if no decrease) on stable or increasing doses of corticosteroids; a significant increase in T2/FLAIR nonenhancing lesions on stable or increasing doses of corticosteroids compared with the baseline scan or the best response after initiation of therapy, not due to comorbid events; the appearance of any new lesions; clear progression of nonmeasurable lesions; or definite clinical deterioration not attributable to other causes apart from the tumor or to a decrease in the corticosteroid dose. (NCT03022578)
Timeframe: From date of enrollment in study to the date of first observation of progressive disease, death due to disease (event), or early discontinuation of treatment, approximately 3 years 3 months

Interventionweeks (Median)
Treatment (LITT, Lomustine)30

[back to top]

Overall Survival (OS)

Overall Survival (OS) is the time from initial tumor diagnosis (definitive surgical resection or biopsy) to death from any cause. Will be estimated using the Kaplan-Meier method and the comparison between or among patient's characteristic groups will be evaluated by log-rank test. The Cox regression model may be applied to assess the effect of covariates of interest on OS. (NCT03022578)
Timeframe: approximately 3 years 3 months

Interventionweeks (Median)
Treatment (LITT, Lomustine)69

[back to top]

Median PFS

"Progression-free Survival defined as number of months from the date of the first dose of study drug to the first observation of a disease progression or death due to any cause.~Progression is assessed according to Response Assessment in Neuro-Oncology (RANO) 2010 criteria based on MRI imaging, and includes ≥25% increase in the sum of the products of perpendicular diameters of enhancing lesions (compared with baseline if no decrease) on stable or increasing doses of corticosteroids." (NCT03463265)
Timeframe: Through study completion (up to 48 months)

Interventionmonths (Median)
Arm A, Cohort 1: Nab-sirolimus in Patients With Recurrent High Grade Glioma1.7
Arm A, Cohort 2: Nab-sirolimus + Temozolomide in Patients With Recurrent High Grade Glioma11.3
Arm A, Cohort 3: Nab-sirolimus + Bevacizumab in Patients With Recurrent High Grade Glioma3.1
Arm A, Cohort 4: Nab-sirolimus + Lomustine in Patients With Recurrent High Grade Glioma3.8
Arm A, Cohort 5: Nab-sirolimus + Marizomib in Patients With Recurrent High Grade Glioma1.7
Arm B: Nab-sirolimus + Temozolomide + Radiotherapy in Patients With Newly Diagnosed Glioblastoma7.5

[back to top]

OS

Median Overall Survival (NCT03463265)
Timeframe: Through study completion (up to 48 months)

Interventionmonths (Median)
Arm A, Cohort 1: Nab-sirolimus in Patients With Recurrent High Grade Glioma7.2
Arm A, Cohort 2: Nab-sirolimus + Temozolomide in Patients With Recurrent High Grade Glioma13.8
Arm A, Cohort 3: Nab-sirolimus + Bevacizumab in Patients With Recurrent High Grade Glioma6.8
Arm A, Cohort 4: Nab-sirolimus + Lomustine in Patients With Recurrent High Grade Gliom7.5
Arm A, Cohort 5: Nab-sirolimus + Marizomib in Patients With Recurrent High Grade Glioma6.7
Arm B: Nab-sirolimus + Temozolomide + Radiotherapy in Patients With Newly Diagnosed Glioblastoma13.3

[back to top]

OS at 12 Months

Overall Survival rate at 12 months (NCT03463265)
Timeframe: 12 months

Interventionpercentage of patients (Number)
Arm A, Cohort 1: Nab-sirolimus in Patients With Recurrent High Grade Glioma0.0
Arm A, Cohort 2: Nab-sirolimus + Temozolomide in Patients With Recurrent High Grade Glioma66.7
Arm A, Cohort 3: Nab-sirolimus + Bevacizumab in Patients With Recurrent High Grade Glioma25.0
Arm A, Cohort 4: Nab-sirolimus + Lomustine in Patients With Recurrent High Grade Glioma25.0
Arm A, Cohort 5: Nab-sirolimus + Marizomib in Patients With Recurrent High Grade Glioma0.0
Arm B: Nab-sirolimus + Temozolomide + Radiotherapy in Patients With Newly Diagnosed Glioblastoma53.8

[back to top]

PFS Rate at 6 Months and 12 Months

"Progression-free survival rate at 6 months and 12 months was calculated as the proportion of patients who were progression-free and alive at 6 and 12 months, respectively.~Progression is assessed according to Response Assessment in Neuro-Oncology (RANO) 2010 criteria based on MRI imaging, and includes ≥25% increase in the sum of the products of perpendicular diameters of enhancing lesions (compared with baseline if no decrease) on stable or increasing doses of corticosteroids." (NCT03463265)
Timeframe: 6 and 12 months

,,,,,
Interventionpercentage of patients (Number)
PFS at 6 monthsPFS at 12 months
Arm A, Cohort 1: Nab-sirolimus in Patients With Recurrent High Grade Glioma0.00.0
Arm A, Cohort 2: Nab-sirolimus + Temozolomide in Patients With Recurrent High Grade Glioma75.050.0
Arm A, Cohort 3: Nab-sirolimus + Bevacizumab in Patients With Recurrent High Grade Glioma37.512.5
Arm A, Cohort 4: Nab-sirolimus + Lomustine in Patients With Recurrent High Grade Glioma25.00.0
Arm A, Cohort 5: Nab-sirolimus + Marizomib in Patients With Recurrent High Grade Glioma10.00.0
Arm B: Nab-sirolimus + Temozolomide + Radiotherapy in Patients With Newly Diagnosed Glioblastoma76.936.4

[back to top]

ORR

Objective overall response rate (ORR, according to Response Assessment in Neuro-Oncology [RANO]) by investigator-assessed radiologic review and defined as the proportion of patients who achieved a confirmed partial response (PR) or confirmed complete response (CR) per RANO 2010 criteria. PR is defined as greater than or equal to 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions sustained for at least 4 weeks. (NCT03463265)
Timeframe: Through study completion (up to 48 months)

Interventionpercentage of patients (Number)
Arm A, Cohort 1: Nab-sirolimus in Patients With Recurrent High Grade Glioma0
Arm A, Cohort 2: Nab-sirolimus + Temozolomide in Patients With Recurrent High Grade Glioma0
Arm A, Cohort 3: Nab-sirolimus + Bevacizumab in Patients With Recurrent High Grade Glioma0
Arm A, Cohort 4: Nab-sirolimus + Lomustine in Patients With Recurrent High Grade Glioma0
Arm A, Cohort 5: Nab-sirolimus + Marizomib in Patients With Recurrent High Grade Glioma0
Arm B: Nab-sirolimus + Temozolomide + Radiotherapy in Patients With Newly Diagnosed Glioblastoma11.5

[back to top]